(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 16 August 2001 (16.08.2001)

PCT

(10) International Publication Number WO 01/59122 A1

- (51) International Patent Classification⁷: C1 15/82, 15/11, C07K 14/415, A01H 5/00
- C12N 15/29,
- (21) International Application Number: PCT/SG01/00017
- (22) International Filing Date: 1 February 2001 (01.02.2001)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: PCT/SG00/00022

11 February 2000 (11.02.2000) SG

- (71) Applicant (for all designated States except US): INSTITUTE OF MOLECULAR AGROBIOLOGY [SG/\$G]; National University of Singapore, 1 Research Link, Singapore 117604 (SG).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SUNDARESAN, Venkatesan [US/SG]; 465 Pasir Panjang Road, Singapore 118798 (SG). RAJANI, Sarojam [IN/SG]; Apt. Blk 609 #04-92, Clementi West Street 1, Singapore 120609 (SG).

- (74) Agent: MIRANDAH, Gladys; Ella Cheong & G. Mirandah, 111 North Bridge Road, #22-01/02/03 Peninsula Plaza. Singapore 179098 (SG).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



(54) Title: DEHISCENCE GENE AND METHODS FOR REGULATING DEHISCENCE

(57) Abstract: The present invention is directed to the prevention of the dispersal of seeds through the process of dehiscence (pod shattering), which leads to significant seed loss during harvesting of crops. We have identified and characterized the SGT10166 gene in Arabidopsis thaliana and mutations of the gene that prevent dehiscence of the mature fruit. The gene encodes a protein that was found to be similar to the basic Helix-loop-Helix class of transcription factors. The expression pattern of the gene and the phenotype of the mutant plants indicates its likely role in enabling silique dehiscence.

. 1

TITLE OF THE INVENTION

DEHISCENCE GENE AND METHODS FOR REGULATING DEHISCENCE

BACKGROUND OF THE INVENTION

The present invention is directed to a mutation in *Arabidopsis thaliana* which prevents dehiscence (pod shattering) of the mature fruit. The isolated gene is identified as *SGT10166* and encodes a protein that was found to be similar to the basic Helix-loop-Helix class of transcription factors. The expression pattern of the gene and the phenotype of the mutant plants indicates its role in silique dehiscence.

The publications and other materials used herein to illuminate the background of the invention or provide additional details respecting the practice are respectively grouped in the appended Lists of References.

The fruit is a specialized plant organ which is responsible for the maturation and dispersal of seeds. Dispersal of seeds occurs through a process of dehiscence, e.g., where a seed pod opens to release the seeds therein. Dehiscence is of agronomic importance in crops like *Brassica sp.*, where it leads to significant seed loss during harvest.

The fruit of *Arabidopsis* is known as silique, which develops from a fertilized gynoecium. The gynoecium consists of an apical stigma, a style and a basal ovary. The ovary consists of two carpels that share a fused tissue called septum. The walls of the carpel are known as valves, which are joined to the replum. The replum represents the outer margin of the septum (Sessions, 1999). After fertilization, the gynoecium expands to form an elongated silique. Dispersal of seeds occurs through a process of dehiscence where the silique opens to release the seeds. Dehiscence in *Arabidopsis* requires the development of a dehiscence zone along the replum-valve junction which allows the valves to detach from the replum, releasing the seeds (Gu et al., 1998).

Thus, there is a continued need to investigate genes involved in the dispersal of seeds through the process of dehiscence as the prevention of dehiscence in crops would significantly minimize seed loss during harvest.

It is also desired to identify plant genes which are involved with dehiscence in order to derive promoter and/or enhancer and/or intron sequences for use in preparing transgenic plants or in order to interfere with normal dehiscence in transgenic plants to produce indehiscent plants.

SUMMARY OF THE INVENTION

The present invention is directed to a gene which is involved in dehiscence, mutations in the gene which prevent dehiscence and constructs which inhibit the activity of the gene product. The present invention is further directed to the prevention of the dispersal of seeds through the process of dehiscence (pod shattering), which leads to significant seed loss during harvesting of crops. In accordance with the present invention, we have identified a gene in *Arabidopsis thaliana* which is involved in dehiscence and a mutation thereof which prevents dehiscence of the mature fruit (silique). The gene encodes a protein that was found to be similar to the basic Helix-loop-Helix class of transcription factors.

In a one aspect, the present invention is directed to the identification and characterization of the SGT10166 gene in Arabidopsis thaliana.

In a second aspect, the present invention is directed to mutations in *Arabidopsis thaliana* and other plants that prevent dehiscence of the mature fruit.

In a third aspect of the invention, constructs comprising at least a portion of an SGT10166 nucleic acid are provided for altering dehiscence of the mature fruit. The constructs generally comprise a heterologous promoter, i.e., one not naturally associated with the SGT10166 gene, operably linked to the SGT10166 nucleic acid. The SGT10166 may be in sense or antisense orientation with respect to the promoter. Vectors containing the construct for use in transforming plant cells are also provided. Any plant cells can be transformed in accordance with the present invention. Preferred plant cells are plant cells of plants which develop fruit, e.g., silique, which develops from a fertilized gynoecium to produce seeds in a pod.

In a fourth aspect of the invention, plants having at least one cell transformed with a construct containing SGT10166 nucleic acid for altering dehiscence of the mature fruit is provided. Such plants have a phenotype characterized by altered dehiscence. Preferred plant cells are plant cells of plants which develop fruit, e.g., silique, which develops from a fertilized gynoecium to produce seeds in a pod.

In a fifth aspect of the invention, methods for producing plants having altered dehiscence are provided. The methods comprise the steps of transforming plant cells with a vector comprising at least a portion of an SGT10166 nucleic acid, regenerating plants from one or more of the transformed plant cells and selecting at least one plant exhibiting altered dehiscence.

In a sixth aspect of the invention, a promoter, an enhancer and/or an intron of the Arabidopsis SGT10166 gene are provided.

In a seventh aspect of the invention, gene constructs comprising the promoter and/or enhancer and/or intron of the SGT10166 gene and a heterologous gene are provided. Vectors containing these constructs are also provided. Plants having at least one cell containing these constructs are further provided by the invention.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 depicts the structure of wild type gynoecium. Sg - Stigma; St - Style; O- Ovary; R - Replum; V - Valve.

Figure 2 depicts the GUS expression pattern of SGT10166 in developing silique, in the order of increasing age (left to right).

Figure 3 depicts the indehiscent phenotype of SGT10166, where (a) is the mature wild type silique, and (b) is the mature SGT10166 silique.

Figure 4(a) depicts the cDNA (SEQ ID NO:1) and deduced amino acid sequence (SEQ ID NO:2) of SGT10166. Fig. 4(b) depicts a sequence comparison of SGT10166 to some plant myc proteins (SEQ ID NOs:3-6).

Figure 5 shows the genomic sequence flanking the *Ds* insertion site and the footprint analysis. (1) Region of wildtype *ALC* locus prior to *DsG* insertion (SEQ ID NO:8). (2) Sequence alteration at *ALC* locus after *Ds* insertion. Nucleotides in bold represent the bases added during *Ds* insertion (SEQ ID NOs:9 and 10). (3) and (4) show the 9 base pair and 10 base pair footprint (in bold) observed after *Ds* excision (SEQ ID NOs:11 and 12).

BRIEF DESCRIPTION OF THE SEQUENCES

SEQ ID NO:1 is the nucleotide sequence for the cDNA of SGT10166.

SEQ ID NO:2 is amino acid sequence for the SGT10166 polypeptide.

SEQ ID NO:3 is the nucleotide sequence for the genomic DNA of SGT10166.

SEQ ID NO:4 is amino acid sequence for the rd22BPI polypeptide.

SEQ ID NO:5 amino acid sequence for the PG1 polypeptide.

SEQ ID NO:6 amino acid sequence for the Lc polypeptide.

SEQ ID NO:7 amino acid sequence for the B-Peru polypeptide.

SEQ ID NO:8 is a region of wildtype ALC locus prior to DsG insertion.

SEQ ID NO:9 is a region of the ALC locus after Ds insertion.

SEQ ID NO:10 is a region of the ALC locus after Ds insertion.

SEQ ID NO:11 is a region of the ALC locus of a revertant after Ds excision.

SEQ ID NO:12 is a region of the ALC locus (alc10) after Ds excision.

SEQ ID NO:13 is the DNA fragment deleted from SEQ ID NO:1 and which encodes a basic peptide domain and is replaced by a sequence encoding an acidic domain in SEQ ID NO:14.

SEQ ID NO:15 is the dominant negative DNA construct created by deleting the basic domain encoding portion (SEQ ID NO:13) of SGT10166 and inserting SEQ ID NO:14.

SEQ ID NO:16 is the protein encoded by SEQ ID NO:14.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a gene involved in dehiscence and to mutations in the gene which prevent dehiscence (pod shattering) of the mature fruit. The SGT10166 gene encodes a protein similar to the basic Helix-loop-Helix class of transcription factors. The expression pattern of the gene and the phenotype of the mutant plants indicates its role in enabling silique dehiscence.

In accordance with the present invention, a gene is provided which is involved in dehiscence. This gene was discovered by identifying an *Arabidopsis* line containing a mutation which prevented dehiscence. More specifically, the isolated gene encodes a protein that was found to be similar to the basic Helix-loop-Helix class of transcription factors. It was found that the protein product was found in the gynoecium as more fully described in Example 2. The cDNA coding for the wild-type gene was discovered on the basis of the mutant gene, as more fully described in Example 3. The *Arabidopsis* gene can be used to screen genomic DNA of plants having seed pods to identify homologous genes, which provide additional nucleic acids for use in inhibiting dehiscence. The gene identified in accordance with the present invention is termed the *SGT10166* gene.

The process of dehiscence, commonly known as pod shatter, is of agronomic importance in crops such as oil seed rape (*Brassica napus*) which results in seed loss causing low yields. The losses can be as high as 50% under adverse conditions (Coupe et al., 1994). The mutant line

SGT10166 shows an indehiscent phenotype whereby the silique fail to open, and the protein resembles the bHLH family of proteins. Thus, the SGT10166 gene and homologous genes are useful for making plants which have an indehiscent phenotype. The indehiscent phenotype can be accomplished using an anti-sense or a dominant negative approach. For the antisense approach (Gray et al., 1992), it may be necessary to first clone the corresponding gene from the desired crop plant by DNA homology to the SGT10166 gene. Dominant negative regulators can be made by deleting or mutating the DNA binding domain of the protein (Krylov et al., 1997). Such HLH proteins act as dominant negative regulators by sequestering bHLH proteins to form inactive protein dimers. In this approach, the Arabidopsis gene may be used directly.

Methods of interfering with gene function in a transgenic plant include introducing a synthetic gene that causes sense or antisense suppression of the target gene (Taylor and Jorgensen, 1992). The suppression methods require substantial similarity between the target gene and the suppressing gene, greater than 80% nucleotide sequence identity (Mol et al., 1994).

As described in further detail herein, the SGT10166 gene can be used to prevent normal dehiscence of the mature fruit in plants. Briefly, two techniques for using the SGT10166 gene for this purpose are antisense or sense suppression to decrease the level of expression of the endogenous SGT10166 gene. A third technique is to use the regulatory sequences of SGT10166 to direct expression of a lethal gene product specifically in fruit tissues (genetic ablation).

Definitions

The present invention employs the following definitions, which are, where appropriate, referenced to SGT10166.

"Altered dehiscence" or "modified dehiscence phenotype" refers to a physical modification in the structure of a plant's silique tissue as compared to the parent plant from which the plant having the modified phenotype is obtained. Macroscopic alterations may include changes in the size, shape, number or location of fruit organs. Microscopic alterations may include changes in the types or shapes of cells that make up the fruit structures. Such modified fruit phenotypes can be uniform throughout the plant and typically arise when each of the cells within the plant contain cells transformed with a vector comprising at least a portion of the SGT10166 nucleic acid. Such plants are sometimes referred to as transgenic plants. The phenotype produced in a particular plant is dependent upon the design of the vector used to produce it. Thus, the vector can be designed to transcribe a nucleic acid which encodes at least

a portion of the SGT10166 protein. In such cases, the SGT10166 protein so produced is capable of conferring a particular phenotype based on the presence of that protein within the cell. Alternatively, the vector can be constructed such that transcription results in the formation of a transcript which is capable of hybridizing with an RNA transcript of an endogenous SGT10166 or a homolog gene. This approach employs the well known antisense technology and results in a modulation in the phenotypic effect of the endogenous SGT10166 genes. Such modulation of the endogenous SGT10166 gene can also potentially be obtained by using the sense strand of the SGT10166 gene to cause sense suppression of the endogenous SGT10166 alleles as well as the SGT10166 gene introduced in the vector. The production of a plant containing such a phenotype is contemplated based upon the sense suppression observed in Petunia hybrida as set forth in PCT Publication W0 90/12084. The vector may comprise the SGT10166 promoter regulating transcription of a gene encoding a protein that interferes will cell growth. In such cases, the altered dehiscence exhibited may be severe atrophy or loss of fruit structures.

"Amplification of polynucleotides" utilizes methods such as the polymerase chain reaction (PCR), ligation amplification (or ligase chain reaction, LCR) and amplification methods based on the use of Q-beta replicase. Also useful are strand displacement amplification (SDA), thermophilic SDA, and nucleic acid sequence based amplification (3SR or NASBA). These methods are well known and widely practiced in the art. See, e.g., U.S. Patents 4,683,195 and 4,683,202 and Innis et al. (1990) (for PCR); Wu and Wallace (1989) (for LCR); U.S. Patents 5,270,184 and 5,455,166 and Walker et al. (1992) (for SDA); Spargo et al. (1996) (for thermophilic SDA) and U.S. Patent 5,409,818, Fahy et al. (1991) and Compton (1991) (for 3SR and NASBA). Reagents and hardware for conducting PCR are commercially available. Primers useful to amplify sequences from the *SGT10166* region are preferably complementary to, and hybridize specifically to sequences in the *SGT10166* region or in regions that flank a target region therein. *SGT10166* sequences generated by amplification may be sequenced directly. Alternatively, but less desirably, the amplified sequence(s) may be cloned prior to sequence analysis. A method for the direct cloning and sequence analysis of enzymatically amplified genomic segments has been described by Scharf et al. (1986).

"Analyte polynucleotide" and "analyte strand" refer to a single- or double-stranded polynucleotide which is suspected of containing a target sequence, and which may be present in a variety of types of samples, including biological samples.

"Binding partner" refers to a molecule capable of binding a ligand molecule with high specificity, as for example, complementary polynucleotide strands or an enzyme and its inhibitor. In general, the specific binding partners must bind with sufficient affinity to immobilize the analyte copy/complementary strand duplex (in the case of polynucleotide hybridization) under the isolation conditions. In the case of complementary polynucleotide binding partners, the partners are normally at least about 15 bases in length, and may be at least 40 bases in length. It is well recognized by those of skill in the art that lengths shorter than 15 (e.g., 8 bases), between 15 and 40, and greater than 40 bases may also be used. The polynucleotides may be composed of DNA, RNA, or synthetic nucleotide analogs. Further binding partners can be identified using, e.g., the two-hybrid yeast screening assay as described herein.

A "biological sample" refers to a sample of tissue or fluid suspected of containing an analyte polynucleotide or polypeptide from a plant including, but not limited to, e.g., pollen, ovules, cells, organs, tissue and samples of *in vitro* cell culture constituents.

"Encode". A polynucleotide is said to "encode" a polypeptide if, in its native state or when manipulated by methods well known to those skilled in the art, it can be transcribed and/or translated to produce the mRNA for and/or the polypeptide or a fragment thereof. The anti-sense strand is the complement of such a nucleic acid, and the encoding sequence can be deduced therefrom.

"Isolated" or "substantially pure". An "isolated" or "substantially pure" nucleic acid (e.g., an RNA, DNA or a mixed polymer) is one which is substantially separated from other cellular components which naturally accompany a native plant sequence or protein, e.g., ribosomes, polymerase, many other plant genome sequences and proteins. The term embraces a nucleic acid sequence or protein which has been removed from its naturally occurring environment, and includes recombinant or cloned DNA isolates and chemically synthesized analogs or analogs biologically synthesized by heterologous systems.

"SGT10166 allele" refers, respectively, to normal alleles of the SGT10166 locus as well as alleles of SGT10166 having variations, isolated from plants or produced in accordance with the present invention.

"SGT10166 locus", "SGT10166 gene", "SGT10166 nucleic acids" or "SGT10166 polynucleotide" each refer to polynucleotides, all of which are in the SGT10166 region, respectively, that are likely to be expressed in normal tissue and involved in dehiscence. The

SGT10166 locus is intended to include coding sequences, intervening sequences and regulatory elements (e.g., promoters and enhancers) controlling transcription and/or translation. The SGT10166 locus is intended to include all allelic variations of the DNA sequence.

These terms, when applied to a nucleic acid, refer to a nucleic acid which encodes a plant SGT10166 polypeptide, fragment, homolog or variant, including, e.g., protein fusions or deletions. The nucleic acids of the present invention will possess a sequence which is either derived from, or substantially similar to, a natural SGT10166-encoding gene or one having substantial homology with a natural SGT10166-encoding gene or a portion thereof. The term SGT10166 nucleic acid is sometimes used to refer to the sense and antisense strands of the SGT10166 gene collectively.

The SGT10166 gene or nucleic acid includes normal alleles of the SGT10166 gene, respectively, including silent alleles having no effect on the amino acid sequence of the SGT10166 polypeptide as well as alleles leading to amino acid sequence variants of the SGT10166 polypeptide that do not substantially affect its function. These terms also include alleles having one or more mutations which adversely affect the function of the SGT10166 polypeptide. A mutation may be a change in the SGT10166 nucleic acid sequence which produces a deleterious change in the amino acid sequence of the SGT10166 polypeptide, resulting in partial or complete loss of SGT10166 function, respectively, or may be a change in the nucleic acid sequence which results in the loss of effective SGT10166 expression or the production of aberrant forms of the SGT10166 polypeptide.

The SGT10166 nucleic acid may be that shown in SEQ ID NO:1 or it may be an allele as described above or a variant or derivative differing from that shown by a change which is one or more of addition, insertion, deletion and substitution of one or more nucleotides of the sequence shown. Changes to the nucleotide sequence may result in an amino acid change at the protein level, or not, as determined by the genetic code.

Thus, nucleic acid according to the present invention may include a sequence different from the sequence shown in SEQ ID NO:1 yet encode a polypeptide with the same amino acid sequence as shown in SEQ ID NO:2. That is, nucleic acids of the present invention include sequences which are degenerate as a result of the genetic code. On the other hand, the encoded polypeptide may comprise an amino acid sequence which differs by one or more amino acid residues from the amino acid sequence shown in SEQ ID NO:2. Nucleic acid encoding a

polypeptide which is an amino acid sequence variant, derivative or allele of the amino acid sequence shown in SEQ ID NO:2 is also provided by the present invention.

The SGT10166 gene, respectively, also refers to (a) any DNA sequence that (i) hybridizes to the complement of the DNA sequences that encode the amino acid sequence set forth in SEQ ID NO:2 under highly stringent conditions (Ausubel et al., 1992) and (ii) encodes a gene product functionally equivalent to SGT10166, or (b) any DNA sequence that (i) hybridizes to the complement of the DNA sequences that encode the amino acid sequence set forth in SEQ ID NO:2 under less stringent conditions, such as moderately stringent conditions (Ausubel et al., 1992) and (ii) encodes a gene product functionally equivalent to SGT10166. The invention also includes nucleic acid molecules that are the complements of the sequences described herein.

The polynucleotide compositions of this invention include RNA, cDNA, genomic DNA, synthetic forms, and mixed polymers, both sense and antisense strands, and may be chemically or biochemically modified or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those skilled in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), pendent moieties (e.g., polypeptides), intercalators (e.g., acridine, psoralen, etc.), chelators, alkylators, and modified linkages (e.g., alpha anomeric nucleic acids, etc.). Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen bonding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.

The present invention provides recombinant nucleic acids comprising all or part of the SGT10166 region. The recombinant construct may be capable of replicating autonomously in a host cell. Alternatively, the recombinant construct may become integrated into the chromosomal DNA of the host cell. Such a recombinant polynucleotide comprises a polynucleotide of genomic, cDNA, semi-synthetic, or synthetic origin which, by virtue of its origin or manipulation, 1) is not associated with all or a portion of a polynucleotide with which it is associated in nature; 2) is linked to a polynucleotide other than that to which it is linked in nature; or 3) does not occur in nature. Where nucleic acid according to the invention includes

RNA, reference to the sequence shown should be construed as reference to the RNA equivalent, with U substituted for T.

Therefore, recombinant nucleic acids comprising sequences otherwise not naturally occurring are provided by this invention. Although the wild-type sequence may be employed, it may also be altered, e.g., by deletion, substitution or insertion. cDNA or genomic libraries of various types may be screened as natural sources of the nucleic acids of the present invention, or such nucleic acids may be provided by amplification of sequences resident in genomic DNA or other natural sources, e.g., by PCR. The choice of cDNA libraries normally corresponds to a tissue source which is abundant in mRNA for the desired proteins. Phage libraries are normally preferred, but other types of libraries may be used. Clones of a library are spread onto plates, transferred to a substrate for screening, denatured and probed for the presence of desired sequences.

The DNA sequences used in this invention will usually comprise at least about five codons (15 nucleotides), more usually at least about 7-15 codons, and most preferably, at least about 35 codons. One or more introns may also be present. This number of nucleotides is usually about the minimal length required for a successful probe that would hybridize specifically with an SGT10166-encoding sequence. In this context, oligomers of as low as 8 nucleotides, more generally 8-17 nucleotides, can be used for probes, especially in connection with chip technology.

Techniques for nucleic acid manipulation are described generally, e.g., in Sambrook et al. (1989) or Ausubel et al. (1992). Reagents useful in applying such techniques, such as restriction enzymes and the like, are widely known in the art and commercially available from such vendors as New England BioLabs, Boehringer Mannheim, Amersham, Promega, U.S. Biochemicals, New England Nuclear, and a number of other sources. The recombinant nucleic acid sequences used to produce fusion proteins of the present invention may be derived from natural or synthetic sequences. Many natural gene sequences are obtainable from various cDNA or from genomic libraries using appropriate probes. See, GenBank, National Institutes of Health.

As used herein, a "portion" of the SGT10166 locus or region or allele is defined as having a minimal size of at least about eight nucleotides, or preferably about 15 nucleotides, or more preferably at least about 25 nucleotides, and may have a minimal size of at least about 40 nucleotides. This definition includes all sizes in the range of 8-40 nucleotides as well as greater

than 40 nucleotides. Thus, this definition includes nucleic acids of 8, 12, 15, 20, 25, 40, 60, 80, 100, 200, 300, 400, 500 nucleotides, or nucleic acids having any number of nucleotides within these ranges of values (e.g., 9, 10, 11, 16, 23, 30, 38, 50, 72, 121, etc., nucleotides), or nucleic acids having more than 500 nucleotides. The present invention includes all novel nucleic acids having at least 8 nucleotides derived from SEQ ID NO:1, its complement or functionally equivalent nucleic acid sequences. The present invention does not include nucleic acids which exist in the prior art. That is, the present invention includes all nucleic acids having at least 8 nucleotides derived from SEQ ID NO:1 with the proviso that it does not include isolated nucleic acids existing in the prior art.

"SGT10166 protein" or "SGT10166 polypeptide" refers to a protein or polypeptide encoded by the SGT10166 locus, variants or fragments thereof. The term "polypeptide" refers to a polymer of amino acids and its equivalent and does not refer to a specific length of the product; thus, peptides, oligopeptides and proteins are included within the definition of a polypeptide. This term also does not refer to, or exclude modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations, and the like. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages as well as other modifications known in the art, both naturally and non-naturally occurring. Ordinarily, such polypeptides will be at least about 50% homologous to the native SGT10166 sequence, preferably in excess of about 90%, and more preferably at least about 95% homologous. Also included are proteins encoded by DNA which hybridize under high or low stringency conditions, to SGT10166-encoding nucleic acids and closely related polypeptides or proteins retrieved by antisera to the SGT10166 protein(s).

The SGT10166 polypeptide may be that shown in SEQ ID NO:2 which may be in isolated and/or purified form, free or substantially free of material with which it is naturally associated. The polypeptide may, if produced by expression in a prokaryotic cell or produced synthetically, lack native post-translational processing, such as glycosylation. Alternatively, the present invention is also directed to polypeptides which are sequence variants, alleles or derivatives of the SGT10166 polypeptide. Such polypeptides may have an amino acid sequence which differs from that set forth in SEQ ID NO:2 by one or more of addition, substitution, deletion or insertion of one or more amino acids. In one embodiment, these variant polypeptides

have a function similar to SGT10166 such that they can be used to restore fertility or used in place of homologous genes. In a second embodiment, these variant peptides do not retain the SGT10166 function such that they can be used as a dominant negative.

Substitutional variants typically contain the exchange of one amino acid for another at one or more sites within the protein, and may be designed to modulate one or more properties of the polypeptide, such as stability against proteolytic cleavage, without the loss of other functions or properties. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. Preferred substitutions are ones which are conservative, that is, one amino acid is replaced with one of similar shape and charge. Conservative substitutions are well known in the art and typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and tyrosine, phenylalanine.

Certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules or binding sites on proteins interacting with the SGT10166 polypeptide. Since it is the interactive capacity and nature of a protein which defines that protein's biological functional activity, certain amino acid substitutions can be made in a protein sequence, and its underlying DNA coding sequence, and nevertheless obtain a protein with like properties. In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydrophobic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte and Doolittle, 1982). Alternatively, the substitution of like amino acids can be made effectively on the basis of hydrophilicity. The importance of hydrophilicity in conferring interactive biological function of a protein is generally understood in the art (U.S. Patent 4,554,101). The use of the hydrophobic index or hydrophilicity in designing polypeptides is further discussed in U.S. Patent 5,691,198.

The length of polypeptide sequences compared for homology will generally be at least about 16 amino acids, usually at least about 20 residues, more usually at least about 24 residues, typically at least about 28 residues, and preferably more than about 35 residues.

"Operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. For instance, a promoter is operably linked to a coding sequence if the promoter affects its transcription or expression.

"Probes". Probes for SGT10166 alleles may be derived from the sequences of the SGT10166 region, its cDNA, functionally equivalent sequences, or the complements thereof. The probes may be of any suitable length, which span all or a portion of the SGT10166 region, and which allow specific hybridization to the region. If the target sequence contains a sequence identical to that of the probe, the probes may be short, e.g., in the range of about 8-30 base pairs, since the hybrid will be relatively stable under even stringent conditions. If some degree of mismatch is expected with the probe, i.e., if it is suspected that the probe will hybridize to a variant region, a longer probe may be employed which hybridizes to the target sequence with the requisite specificity.

The probes will include an isolated polynucleotide attached to a label or reporter molecule and may be used to isolate other polynucleotide sequences, having sequence similarity by standard methods. For techniques for preparing and labeling probes see, e.g., Sambrook et al. (1989) or Ausubel et al. (1992). Other similar polynucleotides may be selected by using homologous polynucleotides. Alternatively, polynucleotides encoding these or similar polypeptides may be synthesized or selected by use of the redundancy in the genetic code. Various codon substitutions may be introduced, e.g., by silent changes (thereby producing various restriction sites) or to optimize expression for a particular system. Mutations may be introduced to modify the properties of the polypeptide, perhaps to change the polypeptide degradation or turnover rate.

Probes comprising synthetic oligonucleotides or other polynucleotides of the present invention may be derived from naturally occurring or recombinant single- or double-stranded polynucleotides, or be chemically synthesized. Probes may also be labeled by nick translation, Klenow fill-in reaction, or other methods known in the art.

Portions of the polynucleotide sequence having at least about eight nucleotides, usually at least about 15 nucleotides, and fewer than about 9 kb, usually fewer than about 1.0 kb, from a polynucleotide sequence encoding *SGT10166* are preferred as probes. This definition therefore includes probes of sizes 8 nucleotides through 9000 nucleotides. Thus, this definition includes probes of 8, 12, 15, 20, 25, 40, 60, 80, 100, 200, 300, 400 or 500 nucleotides or probes having

any number of nucleotides within these ranges of values (e.g., 9, 10, 11, 16, 23, 30, 38, 50, 72, 121, etc., nucleotides), or probes having more than 500 nucleotides. The probes may also be used to determine whether mRNA encoding SGT10166 is present in a cell or tissue. The present invention includes all novel probes having at least 8 nucleotides derived from SEQ ID NO:1 or SEQ ID NO:3, its complement or functionally equivalent nucleic acid sequences. The present invention does not include probes which exist in the prior art. That is, the present invention includes all probes having at least 8 nucleotides derived from SEQ ID NO:1, with the proviso that they do not include probes existing in the prior art.

Similar considerations and nucleotide lengths are also applicable to primers which may be used for the amplification of all or part of the *SGT10166* gene. Thus, a definition for primers includes primers of 8, 12, 15, 20, 25, 40, 60, 80, 100, 200, 300, 400, 500 nucleotides, or primers having any number of nucleotides within these ranges of values (e.g., 9, 10, 11, 16, 23, 30, 38, 50, 72, 121, etc. nucleotides), or primers having more than 500 nucleotides, or any number of nucleotides between 500 and 9000. The primers may also be used to determine whether mRNA encoding *SGT10166* is present in a cell or tissue. The present invention includes all novel primers having at least 8 nucleotides derived from the *SGT10166* locus for amplifying the *SGT10166* gene, its complement or functionally equivalent nucleic acid sequences. The present invention does not include primers which exist in the prior art. That is, the present invention includes all primers having at least 8 nucleotides with the proviso that it does not include primers existing in the prior art.

"Protein purification" refers to various methods for the isolation of the SGT10166 polypeptides from other biological material, such as from cells transformed with recombinant nucleic acids encoding SGT10166, and are well known in the art. For example, such polypeptides may be purified by immunoaffinity chromatography employing, e.g., antibodies prepared against SGT10166 using conventional techniques. Various methods of protein purification are well known in the art, and include those described in Deutscher (1990) and Scopes (1982).

The terms "isolated", "substantially pure", and "substantially homogeneous" are used interchangeably to describe a protein or polypeptide which has been separated from components which accompany it in its natural state. A monomeric protein is substantially pure when at least about 60 to 75% of a sample exhibits a single polypeptide sequence. A substantially pure protein

will typically comprise about 60 to 90% W/W of a protein sample, more usually about 95%, and preferably will be over about 99% pure. Protein purity or homogeneity may be indicated by a number of means well known in the art, such as polyacrylamide gel electrophoresis of a protein sample, followed by visualizing a single polypeptide band upon staining the gel. For certain purposes, higher resolution may be provided by using HPLC or other means well known in the art which are utilized for purification.

A SGT10166 protein is substantially free of naturally associated components when it is separated from the native contaminants which accompany it in its natural state. Thus, a polypeptide which is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be substantially free from its naturally associated components. A protein may also be rendered substantially free of naturally associated components by isolation, using protein purification techniques well known in the art.

A polypeptide produced as an expression product of an isolated and manipulated genetic sequence is an "isolated polypeptide", as used herein, even if expressed in a homologous cell type. Synthetically made forms or molecules expressed by heterologous cells are inherently isolated molecules.

"Recombinant nucleic acid" is a nucleic acid which is not naturally occurring, or which is made by the artificial combination of two otherwise separated segments of sequence. This artificial combination is often accomplished by either chemical synthesis means, or by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques. Such is usually done to join together nucleic acid segments of desired functions to generate a desired combination of functions. Alternatively, it is performed to replace a codon with a redundant codon encoding the same or a conservative amino acid, while typically introducing or removing a sequence recognition site.

"Regulatory sequences" refers to those sequences normally within 100 kb of the coding region of a locus, but they may also be more distant from the coding region, or they may be located within introns of the gene, which affect the expression of the gene (including transcription of the gene, and translation, splicing, stability or the like of the messenger RNA).

"Substantial homology, similarity or identity". A nucleic acid or fragment thereof is "substantially homologous" ("or substantially similar") to another if, when optimally aligned (with appropriate nucleotide insertions or deletions) with the other nucleic acid (or its

complementary strand), there is nucleotide sequence identity in at least about 60% of the nucleotide bases, usually at least about 70%, more usually at least about 80%, preferably at least about 90%, and more preferably at least about 95-98% of the nucleotide bases.

Identity means the degree of sequence relatedness between two polypeptide or two polynucleotides sequences as determined by the identity of the match between two strings of such sequences. Identity can be readily calculated. While there exist a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term "identity" is well known to skilled artisans (Computational Molecular Biology, Lesk AM, ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith DW, ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin AM and Griffin HG, eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje G, Academic Press, 1987; and Sequence Analysis Primer, Gribskov M and Devereux J, eds., M Stockton Press, New York, 1991). Methods commonly employed to determine identity between two sequences include, but are not limited to those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo and Lipman (1988). Preferred methods to determine identity are designed to give the largest match between the two sequences tested. Such methods are codified in computer programs. Preferred computer program methods to determine identity between two sequences include, but are not limited to, GCG program package (Devereux et al. (1984), BLASTP, BLASTN, FASTA (Altschul et al. (1990); Altschul et al. (1997)).

Alternatively, substantial homology or (similarity or identity) exists when a nucleic acid or fragment thereof will hybridize to another nucleic acid (or a complementary strand thereof) under selective hybridization conditions, to a strand, or to its complement. Selectivity of hybridization exists when hybridization which is substantially more selective than total lack of specificity occurs. Typically, selective hybridization will occur when there is at least about 55% homology over a stretch of at least about 14 nucleotides, preferably at least about 65%, more preferably at least about 75%, and most preferably at least about 90%. See, Kanehisa (1984). The length of homology comparison, as described, may be over longer stretches, and in certain embodiments will often be over a stretch of at least about nine nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 32 nucleotides, and preferably at least about 36 or more nucleotides.

Nucleic acid hybridization will be affected by such conditions as salt concentration, temperature, or organic solvents, in addition to the base composition, length of the complementary strands, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. Stringent temperature conditions will generally include temperatures in excess of 30°C, typically in excess of 37°C, and preferably in excess of 45°C. Stringent salt conditions will ordinarily be less than 1000 mM, typically less than 500 mM, and preferably less than 200 mM. However, the combination of parameters is much more important than the measure of any single parameter. The stringency conditions are dependent on the length of the nucleic acid and the base composition of the nucleic acid and can be determined by techniques well known in the art. See, e.g., Wetmur and Davidson (1968).

Probe sequences may also hybridize specifically to duplex DNA under certain conditions to form triplex or other higher order DNA complexes. The preparation of such probes and suitable hybridization conditions are well known in the art.

The terms "substantial homology" or "substantial identity", when referring to polypeptides, indicate that the polypeptide or protein in question exhibits at least about 30% identity with an entire naturally-occurring protein or a portion thereof, usually at least about 70% identity, more usually at least about 80% identity, preferably at least about 90% identity, and more preferably at least about 95% identity.

Homology, for polypeptides, is typically measured using sequence analysis software. See, e.g., the Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 910 University Avenue, Madison, Wisconsin 53705, as well as the software described above with reference to nucleic acid homology. Protein analysis software matches similar sequences using measures of homology assigned to various substitutions, deletions and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

"Substantially similar function" refers to the function of a modified nucleic acid or a modified protein, with reference to the wild-type SGT10166 nucleic acid or wild-type SGT10166 polypeptide. The modified polypeptide will be substantially homologous to the wild-type

SGT10166 polypeptide and will have substantially the same function. The modified polypeptide may have an altered amino acid sequence and/or may contain modified amino acids. In addition to the similarity of function, the modified polypeptide may have other useful properties, such as a longer half-life. The similarity of function (activity) of the modified polypeptide may be substantially the same as the activity of the wild-type SGT10166 polypeptide. Alternatively, the similarity of function (activity) of the modified polypeptide may be higher than the activity of the wild-type SGT10166 polypeptide. The modified polypeptide is synthesized using conventional techniques, or is encoded by a modified nucleic acid and produced using conventional techniques. The modified nucleic acid is prepared by conventional techniques. A nucleic acid with a function substantially similar to the wild-type SGT10166 gene function produces the modified protein described above.

A polypeptide "fragment", "portion" or "segment" is a stretch of amino acid residues of at least about five to seven contiguous amino acids, often at least about seven to nine contiguous amino acids, typically at least about nine to 13 contiguous amino acids and, most preferably, at least about 20 to 30 or more contiguous amino acids.

The polypeptides of the present invention, if soluble, may be coupled to a solid-phase support, e.g., nitrocellulose, nylon, column packing materials (e.g., Sepharose beads), magnetic beads, glass wool, plastic, metal, polymer gels, cells, or other substrates. Such supports may take the form, for example, of beads, wells, dipsticks, or membranes.

"Target region" refers to a region of the nucleic acid which is amplified and/or detected.

The term "target sequence" refers to a sequence with which a probe, a primer or an antisense will form a stable hybrid under desired conditions.

The practice of the present invention employs, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA and genetics. See, e.g., Maniatis et al. (1982); Sambrook et al. (1989); Ausubel et al. (1992); Glover (1985); Anand (1992); Guthrie and Fink (1991); Weissbach and Weissbach (1986); Zaitlin et al. (1985) and Gelvin et al. (1990).

Methods of Use: Preparation of Recombinant or Chemically Synthesized Nucleic Acids; Vectors. Transformation, Host Cells

Large amounts of the polynucleotides of the present invention may be produced by replication in a suitable host cell. Natural or synthetic polynucleotide fragments coding for a

desired fragment will be incorporated into recombinant polynucleotide constructs, usually DNA constructs, capable of introduction into and replication in a prokaryotic or eukaryotic cell. Usually the polynucleotide constructs will be suitable for replication in a unicellular host, such as yeast or bacteria, but may also be intended for introduction to (with and without integration within the genome) cultured mammalian or plant or other eukaryotic cell lines. Purification of nucleic acids produced by the methods of the present invention are described, e.g., in Sambrook et al. (1989) or Ausubel et al. (1992).

The polynucleotides of the present invention may also be produced by chemical synthesis, e.g., by the phosphoramidite method described by Beaucage and Caruthers (1981) or the triester method according to Matteucci and Caruthers (1981) and may be performed on commercial, automated oligonucleotide synthesizers. A double-stranded fragment may be obtained from the single-stranded product of chemical synthesis either by synthesizing the complementary strand and annealing the strand together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.

Polynucleotide constructs prepared for introduction into a prokaryotic or eukaryotic host may comprise a replication system recognized by the host, including the intended polynucleotide fragment encoding the desired polypeptide, and will preferably also include transcription and translational initiation regulatory sequences operably linked to the polypeptide encoding segment. Expression vectors may include, for example, an origin of replication or autonomously replicating sequence (ARS) and expression control sequences, a promoter, an enhancer and necessary processing information sites, such as ribosome-binding sites, RNA splice sites, polyadenylation sites, transcriptional terminator sequences, and mRNA stabilizing sequences. Such vectors may be prepared by means of standard recombinant techniques well known in the art and discussed, for example, in Sambrook et al. (1989) or Ausubel et al. (1992).

An appropriate promoter and other necessary vector sequences will be selected so as to be functional in the host, and may include, when appropriate, those naturally associated with the *SGT10166* gene. Examples of workable combinations of cell lines and expression vectors are described in Sambrook et al. (1989) or Ausubel et al. (1992); see also, e.g., Metzger et al. (1988). Many useful vectors are known in the art and may be obtained from such vendors as Stratagene, New England Biolabs, Promega Biotech, and others. Promoters such as the trp, lac and phage promoters, tRNA promoters and glycolytic enzyme promoters may be used in prokaryotic hosts.

Useful yeast promoters include promoter regions for metallothionein, 3-phosphoglycerate kinase or other glycolytic enzymes such as enolase or glyceraldehyde-3-phosphate dehydrogenase, enzymes responsible for maltose and galactose utilization, and others. Vectors and promoters suitable for use in yeast expression are further described in Hitzeman et al., EP 73,675A. Appropriate non-native mammalian promoters might include the early and late promoters from SV40 (Fiers et al., 1978) or promoters derived from murine Molony leukemia virus, mouse tumor virus, avian sarcoma viruses, adenovirus II, bovine papilloma virus or polyoma. Insect promoters may be derived from baculovirus. In addition, the construct may be joined to an amplifiable gene (e.g., DHFR) so that multiple copies of the gene may be made. For appropriate enhancer and other expression control sequences, see also Enhancers and Eukaryotic Gene Expression, Cold Spring Harbor Press, Cold Spring Harbor, New York (1983). See also, e.g., U.S. Patent Nos. 5,691,198; 5,735,500; 5,747,469 and 5,436,146. Plant control sequences are disclosed in, for example, U.S. Patent Nos. 5,106,739; 5,322,938; 5,710,267; 5,268,526 and 5,290,294.

While such expression vectors may replicate autonomously, they may also replicate by being inserted into the genome of the host cell, by methods well known in the art.

Expression and cloning vectors will likely contain a selectable marker, a gene encoding a protein necessary for survival or growth of a host cell transformed with the vector. The presence of this gene ensures growth of only those host cells which express the inserts. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxic substances, e.g. ampicillin, neomycin, methotrexate, etc., (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*. The choice of the proper selectable marker will depend on the host cell, and appropriate markers for different hosts are well known in the art.

The vectors containing the nucleic acids of interest can be transcribed *in vitro*, and the resulting RNA introduced into the host cell by well known methods, e.g., by injection (see, Kubo et al., 1988), or the vectors can be introduced directly into host cells by methods well known in the art, which vary depending on the type of cellular host, including electroporation; transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; infection (where the vector is an infectious agent, such as a viral genome); and other methods. See generally, Sambrook et al.

(1989) and Ausubel et al. (1992). The introduction of the polynucleotides into the host cell by any method known in the art, including, *inter alia*, those described above, will be referred to herein as "transformation." The cells into which have been introduced nucleic acids described above are meant to also include the progeny of such cells.

Large quantities of the nucleic acids and polypeptides of the present invention may be prepared by expressing the SGT10166 nucleic acid or portions thereof in vectors or other expression vehicles in compatible prokaryotic or eukaryotic host cells. The most commonly used prokaryotic hosts are strains of Escherichia coli, although other prokaryotes, such as Bacillus subtilis or Pseudomonas may also be used.

Mammalian or other eukaryotic host cells, such as those of yeast, filamentous fungi, plant, insect, or amphibian or avian species, may also be useful for production of the proteins of the present invention. Propagation of mammalian cells in culture is *per se* well known. See, Jakoby and Pastan (eds.) (1979). Examples of commonly used mammalian host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cells, and WI38, BHK, and COS cell lines, although it will be appreciated by the skilled practitioner that other cell lines may be appropriate, e.g., to provide higher expression, desirable glycosylation patterns, or other features. An example of a commonly used insect cell line is SF9.

Clones are selected by using markers depending on the mode of the vector construction. The marker may be on the same or a different DNA molecule, preferably the same DNA molecule. In prokaryotic hosts, the transformant may be selected, e.g., by resistance to ampicillin, tetracycline or other antibiotics. Production of a particular product based on temperature sensitivity may also serve as an appropriate marker.

Prokaryotic or eukaryotic cells transformed with the polynucleotides of the present invention will be useful not only for the production of the nucleic acids and polypeptides of the present invention, but also, for example, in studying the characteristics of SGT10166 polypeptides.

The probes and primers based on the SGT10166 gene sequence disclosed herein are used to identify gene sequences and proteins homologous to SGT10166 in other species. These gene sequences and proteins are used in the diagnostic/prognostic, such as predicting reproductive phenotype in transgenic plants and genetic engineering methods described herein for the species from which they have been isolated.

Methods of Use: Controlling Reproductive Dehiscence

The vectors used to transform plant cells comprise an SGT10166 nucleic acid or homologous nucleic acid or portion thereof which is capable of hybridizing with the endogenous gene homologous to the SGT10166 gene of Arabidopsis. For purposes of description, the invention will be described with reference to the SGT10166 gene and SGT10166 protein. It is understood that such reference also includes homologous genes and proteins." Thus, such nucleic acids include the positive strand of the SGT10166 or homologous gene encoding all or part of a protein and the antisense strand. In either case, the SGT10166 or homologous nucleic acid or its transcript is capable of hybridizing with and endogenous gene as defined herein or its transcript. The conditions under which such hybridization occurs include the physiological or equivalent conditions found within plant cells including that found in the nucleus and cytoplasm as well as standard in vitro conditions normally used by the skilled artisan to determine sequence homology as between two nucleic acids. Such in vitro conditions range from moderate (about 5 × SSC at 52°C) to high (about 0.1 × SSC at 65°C) stringency conditions.

The SGT10166 or homologous gene is used to construct sense or antisense vectors for transforming plant cells. The construction of such vectors is facilitated by the use of a binary vector which is capable of manipulation and selection in both a plant and a convenient cloning host such as a prokaryote. Thus, such a binary vector can include a kanamycin or herbicide resistance gene for selection in plant cells and an actinomycin resistance gene for selection in a bacterial host. Such vectors, of course, also contain an origin of replication appropriate for the prokaryotic host used, and preferably at least one unique restriction site or a polylinker containing unique restriction sites to facilitate vector construction.

In one embodiment, a constitutive promoter is used to drive expression of the SGT10166 nucleic acid within at least a portion of the reproductive tissues in the recipient plant. A particularly preferred promoter is the cauliflower mosaic virus 35S transcript promoter (Guilley et al., 1982; Odell et al., 1985; and Saunders et al., 1987). However, other constitutive promoters can be used, such as the α -1 and β -1 tubulin promoters (Silflow et al., 1987) and the histone promoters (Chaubet et al., 1987). Tissue specific promoters can also be used. For example, the "endogenous" promoter of the SGT10166 gene may be used to drive expression of antisense or dominant negative transgenes in the region where the wild type gene is expressed.

In a further embodiment of the invention, the vector used to transform the plant cell to produce a plant having an altered dehiscence phenotype is constructed to target the insertion of the *SGT10166* or homologous nucleic acid into an endogenous promoter within a plant cell. One type of vector which can be used to target the integration of an *SGT10166* or homologous nucleic acid to an endogenous promoter comprises a positive-negative selection vector analogous to that set forth by Monsour et al. (1988), which describes the targeting of exogenous DNA to a predetermined endogenous locus in mammalian ES cells. Similar constructs utilizing positive and negative selection markers functional in plant cells can be readily designed based upon the identification of the endogenous plant promoter and the sequence surrounding it (Kempin et al., 1997). When such an approach is used, it is preferred that a replacement-type vector be used to minimize the likelihood of reversion to the wild-type phenotype.

The vectors of the invention are designed such that the promoter sequence contained in the vector or the promoter sequence targeted in the plant cell genome are operably linked to the nucleic acid encoding the SGT10166 or homologous gene. When the positive strand of the SGT10166 gene or homologous gene is used to express all or part of the SGT10166 protein, the term "operably linked" means that the promoter sequence is positioned relative to the coding sequence of the agamous nucleic acid such that RNA polymerase is capable of initiating transcription of the SGT10166 nucleic acid from the promoter sequence. In such embodiments it is also preferred to provide appropriate ribosome binding sites, transcription initiation and termination sequences, translation initiation and termination sequences and polyadenylation sequences to produce a functional RNA transcript which can be translated into SGT10166 protein. When an antisense orientation of the SGT10166 nucleic acid is used, all that is required is that the promoter be operably linked to transcribe the SGT10166 antisense strand. Thus, in such embodiments, only transcription start and termination sequences are needed to provide an RNA transcript capable of hybridizing with the mRNA or other RNA transcript from the endogenous SGT10166 gene. In addition to promoters, other expression regulation sequences, such as enhancers, can be added to the vector to facilitate the expression of SGT10166 nucleic acid in vivo.

Once a vector is constructed, the transformation of plants can be carried out in accordance with the invention by essentially any of the various transformation methods known to those skilled in the art of plant molecular biology. Such methods are generally described in

Wu and Grossman (1987). As used herein, the term "transformation" means the alteration of the genotype of a plant cell by the introduction of a nucleic acid sequence. Particular methods for transformation of plant cells include the direct microinjection of the nucleic acid into a plant cell by use of micropipettes. Alternatively, the nucleic acid can be transferred into a plant cell by using polyethylene glycol (Paszkowski et al., 1984). Other transformation methods include electroporation of protoplasts (Fromm et al., 1985); infection with a plant specific virus, e.g., cauliflower mosaic virus (Hohn et al., 1982) or use of transformation sequences from plant specific bacteria such as Agrobacterium tumefaciens, e.g., a Ti plasmid transmitted to a plant cell upon infection by Agrobacterium tumefaciens (Horsch et al., 1984; Fraley et al., 1983). Alternatively, plant cells can be transformed by introduction of nucleic acid contained within the matrix or on the surface of small beads or particles by way of high velocity ballistic penetration of the plant cell (Klein et al., 1987). The nucleic acid introduced with ballistics may be a chimeric oligonucleotide designed to target a small number of mutated bases to a selected segment of the endogenous SGT10166 gene or homologous gene (Beetham et al., 1999). A small number of mutated bases can also be introduced into a selected segment of the endogenous SGT10166 gene using homologous recombination (Kempin et al., 1997).

After the vector is introduced into a plant cell, selection for successful transformation is typically carried out prior to regeneration of a plant. Such selection for transformation is not necessary, but facilitates the selection of regenerated plants having the desired phenotype by reducing wild-type background. Such selection is conveniently based upon the antibiotic resistance and/or herbicide resistance genes which may be incorporated into the transformation vector.

Practically all plants can be regenerated from cultured cells or tissues. As used herein, the term "regeneration" refers to growing a whole plant from a plant cell, a group of plant cells or a plant part. The methods for plant regeneration are well known to those skilled in the art. For example, regeneration from cultured protoplasts is described by Evans et al. (1983); and H. Binding (1985). When transformation is of an organ part, regeneration can be from the plant callus, explants, organs or parts. Such methods for regeneration are also known to those skilled in the art. See, e.g., Wu and Grossman (1987); Weissbach and Weissbach (1986); and Klee et al. (1987).

Once plants have been regenerated, one or more plants are selected based upon a change in the dehiscence phenotype. Such selection can be by visual observation of gross morphological changes in fruit structure, e.g., failure of the seed pod to open, by observation in a change in inflorescence or by observation in changes in microscopic fruit structure, e.g., by electron microscopy and the like.

In those cases wherein a dominant phenotype is conferred upon transformation with a vector containing an *SGT10166* nucleic acid, the alteration in dehiscence may possible result in a sterile plant. In such cases, the plant can be propagated asexually by the taking of cuttings or by tissue culture techniques to produce multiple identical plants. Alternatively, the alteration in dehiscence can be ablated when desired as further described herein.

When the transformed plant is characterized by a recessive phenotype, e.g., when an antisense construct is used which is insufficient to confer the desired phenotype or which confers an intermediate phenotype which does not result in a indehiscence exhibiting plant, such transformed plants can be inbred to homozygosity to obtain the desired phenotype. Such plants may then be asexually propagated or the alteration in dehiscence can be ablated when desired as further described herein.

Either antisense or co-suppression mechanisms using SGT10166 nucleic acids can result in altered dehiscence. Plants having such modified dehiscence phenotypes can be used as model systems for further study of the formation and differentiation of fruit tissue in plants.

Methods of Use: Regulatory Sequences for Plant Transformation

In another aspect of the invention, a DNA molecule is provided which comprises regulatory sequences of the SGT10166 gene operably linked to one or more genes or antisense DNA. The entire genomic sequence for Arabidopsis has been cloned and determined. On the basis of the genomic sequence for SGT10166 disclosed herein, the promoter and/or enhancer and/or termination sequences can be readily determined by examining the genomic sequences in GenBank. The regulatory sequences may be the SGT10166 promoter, intron sequences or termination sequences. The SGT10166 promoter begins at the start of exon 1 in SEQ ID NO:3 and extends upstream by about 2 kb of sequence. At least one regulatory sequence is found in intron 1. The gene or antisense DNA imparts an agronomically useful trait or selectable marker to a transformed plant. In one embodiment, the DNA molecule include the SGT10166 promoter

and an additional nucleotide sequence that influences gene expression. Examples of nucleotide sequences that influence the regulation of heterologous genes include enhancers or activating regions, such as those derived from CaMV 35S, opine synthase genes or other plant genes (U.S. Patent Nos. 5,106,739; 5,322,938; 5,710,267; 5,268,526; 5,290.294). In a second embodiment, a promoter such as CaMV 35S promoter is used with regulatory sequences, such as intron sequences or termination sequences of *SGT10166*. In a third embodiment, an intron of *SGT10166* is inserted into a DNA molecule which will be used to transform plants as a means to easily select or identify transformed tissue in the presence of transforming bacteria. In a fourth embodiment, the DNA molecule is part of an expression vector. In a fifth embodiment, the DNA molecule is part of a transformation vector.

In an additional aspect of the present invention, transformed plant cells and tissues, transformed plants and seeds of transformed plants are provided. The expression of the gene or antisense DNA is regulated by the *SGT10166* regulatory sequences and additional regulatory sequences, if present.

By means of the present invention, agronomic genes and selectable marker genes can be operably linked to *SGT10166* regulatory sequences and expressed in transformed plants. More particularly, plants can be genetically engineered to express various phenotypes of agronomic interest. Such genes included, but are not limited to, those described herein.

1. Genes That Confer Resistance or Tolerance to Pests or Disease

- (A) Plant disease resistance genes. Plant defenses are often activated by specific interaction between the product of a disease resistance (R) gene in the plant and the product of a corresponding avirulence (Avr) gene in the pathogen. A plant variety can be transformed with cloned resistance gene to engineer plants that are resistant to specific pathogen strains. Examples of such genes include, the tomato Cf-9 gene for resistance to Cladosporium fulvum (Jones et al., 1994), the tomato Pto gene, which encodes a protein kinase, for resistance to Pseudomonas syringae pv. tomato (Martin et al., 1993), and the Arabidopsis RSSP2 gene for resistance to Pseudomonas syringae (Mindrinos et al., 1994).
- (B). A *Bacillus thuringiensis* protein, a derivative thereof or a synthetic polypeptide modeled thereon, such as, a nucleotide sequence of a Bt δ -endotoxin gene (Geiser et al., 1986). Moreover, DNA molecules encoding δ -endotoxin genes can be purchased from American Type

Culture Collection (Rockville, MD), under ATCC accession numbers. 40098, 67136, 31995 and 31998.

- (C) A lectin, such as nucleotide sequences of several *Clivia miniata* mannose-binding lectin genes (Van Damme et al., 1994).
- (D) A vitamin binding protein, such as avidin and avidin homologs which are useful as larvicides against insect pests. See U.S. Patent No. 5,659,026.
- (E) An enzyme inhibitor, e.g., a protease inhibitor or an amylase inhibitor. Examples of such genes include a rice cysteine proteinase inhibitor (Abe et al., 1987), a tobacco proteinase inhibitor I (Huub et al., 1993), and an α-amylase inhibitor (Sumitani et al., 1993).
- (F) An insect-specific peptide or neuropeptide which, upon expression, disrupts the physiology of the affected pest. Examples of such genes include, an insect diuretic hormone receptor (Reagan, 1994), an allostatin identified in *Diploptera puntata* (Pratt, 1989), insect-specific, paralytic neurotoxins (U.S. Patent No. 5,266,361).
- (G) An insect-specific venom produced in nature by a snake, a wasp, etc., such as, a scorpion insectotoxic peptide (Pang, 1992).
- (H) An enzyme responsible for a hyperaccumulation of a monoterpene, a sesquiterpene, a steroid, hydroxamic acid, a phenylpropanoid derivative or another non-protein molecule with insecticidal activity.
- (I) An enzyme involved in the modification, including the post-translational modification, of a biologically active molecule; for example, glycolytic enzyme, a proteolytic enzyme, a lipolytic enzyme, a nuclease, a cyclase, a transaminase, an esterase, a hydrolase, a phosphatase, a kinase, a phosphorylase, a polymerase, an elastase, a chitinase and a glucanase, whether natural or synthetic. Examples of such genes include, a callas gene (PCT published application WO93/02197), chitinase-encoding sequences (which can be obtained, for example, from the ATCC under accession numbers 3999637 and 67152), tobacco hookworm chitinase (Kramer et al., 1993) and parsley ubi4-2 polyubiquitin gene (Kawalleck et al., 1993).
- (J) A molecule that stimulates signal transduction. Examples of such molecules include, nucleotide sequences for mung bean calmodulin cDNA clones (Botella et al., 1994), a nucleotide sequence of a maize calmodulin cDNA clone (Griess et al., 1994).
- (K) A hydrophobic moment peptide. See U.S. Patent Nos. 5,659,026 and 5,607,914, the latter teaches synthetic antimicrobial peptides that confer disease resistance.

- (L) A membrane permease, a channel former or a channel blocker, such as, a cecropin-β lytic peptide analog (Jaynes et al., 1993) which renders transgenic tobacco plants resistant to *Pseudomonas solanacearum*.
- (M) A viral protein or a complex polypeptide derived therefrom. For example, the accumulation of viral coat proteins in transformed plant cells imparts resistance to viral infection and/or disease development effected by the virus from which the coat protein gene is derived, as well as by related viruses. Coat protein-mediated resistance has been conferred upon transformed plants against alfalfa mosaic virus, cucumber mosaic virus, tobacco streak virus, potato virus X, potato virus Y, tobacco etch virus, tobacco rattle virus and tobacco mosaic virus. See, for example, Beachy et al. (1990).
- (N) An insect-specific antibody or an immunotoxin derived therefrom. Thus, an antibody targeted to a critical metabolic function in the insect gut would inactivate an affected enzyme, killing the insect. For example, Taylor et al. (1994) shows enzymatic inactivation in transgenic tobacco via production of single-chain antibody fragments.
- (O) A virus-specific antibody. See, for example, Tavladoraki et al. (1993), which shows that transgenic plants expressing recombinant antibody genes are protected from virus attack.
- (P) A developmental-arrestive protein produced in nature by a pathogen or a parasite. Thus, fungal endo α -1,4-D polygalacturonases facilitate fungal colonization and plant nutrient release by solubilizing plant cell wall homo- α -1,4-D-galacturonase (Lamb et al., 1992). The cloning and characterization of a gene which encodes a bean endopolygalacturonase-inhibiting protein is described by Toubart et al. (1992).
- (Q) A developmental-arrestive protein produced in nature by a plant, such as the barley ribosome-inactivating gene, have increased resistance to fungal disease (Longemann et al., 1992).

2. Genes That Confer Resistance or Tolerance to a Herbicide

- (A) A herbicide that inhibits the growing point or meristem, such as an imidazalinone or a sulfonylurea. Exemplary genes in this category code for mutant ALS (Lee et al., 1988) and AHAS enzyme (Miki et al., 1990).
- (B) Glyphosate (resistance imparted by mutant EPSP synthase and aroA genes) and other phosphono compounds such as glufosinate (PAT and bar genes), and pyridinoxy or phenoxy propionic acids and cyclohexones (ACCase inhibitor encoding genes). See, for

- example, U.S. Patent 4,940,835, which discloses the nucleotide sequence of a form of EPSP synthase which can confer glyphosate resistance. A DNA molecule encoding a mutant aroA gene can be obtained under ATCC accession number 39256, and the nucleotide sequence of the mutant gene is disclosed in U.S. Patent 4,769,061. European patent application No. 0 333 033 and U.S. Patent 4,975,374 disclose nucleotide sequences of glutamine synthase genes which confer resistance to herbicides such as L-phosphinothricin. The nucleotide sequence of a phosphinothricin acetyltransferase gene is provided in European application No. 0 242 246. De Greef et al. (1989) describes the production of transgenic plants that express chimeric bar genes coding for phosphinothricin acetyltransferase activity. Exemplary of genes conferring resistance to phenoxy proprionic acids and cyclohexones, such as sethoxydim and haloxyfop, are the Acc1-S1, Acc1-S2 and Acc1-S3 genes described by Marshall et al. (1992).
- (C) A herbicide that inhibits photosynthesis, such as a triazine (psbA and GST genes) and a benzonitrile (nitrilase gene). Przibilla et al. (1991) describes the use of plasmids encoding mutant psbA genes to transform *Chlamydomonas*. Nucleotide sequences for nitrilase genes are disclosed in U.S. Patent 4,810,648, and DNA molecules containing these genes are available under ATCC accession numbers 53435, 67441 and 67442. Cloning and expression of DNA coding for a GST (glutathione S-transferase) is described by Hayes et al. (1992).

3. Genes that Confer Resistance or Tolerance to Environmental Stresses

- (A) Cold, freezing or frost. This includes genes that code for proteins that protect from freezing and for enzymes that synthesize cryoprotective solutes. Examples of such genes are *Arabidopsis COR15a* (Artus et al., 1996) and spinach *CAP160* (Kaye et al., 1998). Also in this category are regulatory genes that control the activity of other cold tolerance genes (PCT International Publication Number WO 98/09521).
- (B) Drought or water stress. Kasuga et al. (1999) report how stress inducible expression of *DREB1A* in transgenic plants increases their tolerance of drought stress. Pilon-Smits et al. (1998) report that expression of bacterial genes for synthesis of trehalose produces tolerance of water stress in transgenic tobacco.
- (C) Salinity or salt stress. Genes that code for proteins that minimize uptake of sodium in the presence of high salt, or cause the plant to sequester sodium in vacuoles, can enable plants to tolerate higher levels of salt in the soil. The wheat *HKT1* potassium transporter, described

by Rubio et al. (1999), is an example of the former. Apse et al. (1999) describe how an *Arabidopsis* Na⁺/H⁺ antiporter can act in the latter manner.

(D) Metals. Protection from the toxic effects of metals such as aluminum and cadmium can be accomplished by transgenic expression of genes that prevent uptake of the metal, or that code for chelating agents that bind the metal ions to prevent them from having a toxic effect. Examples of such genes are *Arabidopsis ALR104* and *ALR108* (Larsen et al., 1998) and genes for the enzymes involved in phytochelatin synthesis (Schafer et al., 1998).

4. Genes That Confer or Contribute to a Value-Added Trait

(A) Modified fatty acid metabolism, for example, by transforming maize or *Brassica* with an antisense gene or stearoyl-ACP desaturase to increase stearic acid content of the plant (Knutzon et al., 1992).

(B) Decreased phytate content

- (1) Introduction of a phytase-encoding gene would enhance breakdown of phytate, adding more free phosphate to the transformed plant, such as the *Aspergillus niger* phytase gene (Van Hartingsveldt et al., 1993).
- (2) A gene could be introduced that reduces phytate content. In maize, for example, this could be accomplished by cloning and then reintroducing DNA associated with the single allele which is responsible for maize mutants characterized by low levels of phytic acid (Raboy et al., 1990).
- (C) Modified carbohydrate composition effected, for example, by transforming plants with a gene coding for an enzyme that alters the branching pattern of starch. Examples of such enzymes include, *Streptococcus mucus* fructosyltransferase gene (Shiroza et al., 1988), *Bacillus subtilis* levansucrase gene (Steinmetz et al., 1985), *Bacillus licheniformis* α-amylase (Pen et al., 1992), tomato invertase genes (Elliot et al., 1993), barley amylase gene (Søgaard et al., 1993), and maize endosperm starch branching enzyme II (Fisher et al., 1993).
- (D) Modified lignin content. The amount or composition of lignin can be altered by increasing or decreasing expression of the biosynthetic enzymes for phenylpropanoid lignin precursors, such as cinnamyl alcohol dehydrogenase (CAD), 4-coumarate:CoA ligase (4CL), and O-methyl transferase (OMT). These and other genes involved in formation of lignin are described in U.S. Patent 5,850,020.

5. Selectable Marker Genes:

(A) Numerous selectable marker genes are available for use in plant transformation including, but not limited to, neomycin phosphotransferase II, hygromycin phosphotransferase, EPSP synthase and dihydropteroate synthase. See, Miki et al. (1993).

Synthesis of genes suitably employed in the present invention can be effected by means of mutually priming long oligonucleotides. See, for example, Ausubel et al. (1990) and Wosnick et al. (1987). Moreover, current techniques which employ the polymerase chain reaction permit the synthesis of genes as large as 6 kilobases in length or longer. See Adang et al. (1993) and Bambot et al. (1993). In addition, genes can readily be synthesized by conventional automated techniques.

EXAMPLES

The present invention is further described in the following examples, which are offered by way of illustration and are not intended to limit the invention in any manner. Standard techniques well known in the art or the techniques specifically described below are utilized.

EXAMPLE 1

Isolation and Mutation Phenotype

Using transposon-mediated gene trap mutagenesis approach, we isolated a mutation that blocks the process of silique dehiscence (Sundaresan et al., 1995).

The SGT10166 mutation was isolated from a collection of independent insertion lines generated using a gene trap Ds transposable element. The two-element transposon system utilizes a maize Ac-Ds transposon and the reporter gene GUS (Sundaresan et al., 1995). In the gene trap insertion line SGT10166, the SGT10166 mutant was identified in the F3 progeny of a gene trap line where the siliques displayed an indehiscent phenotype (Fig. 2). The valves failed to separate from the replum, and the seeds could be harvested only if the fruit was opened manually. Apart from the indehiscent phenotype, the plant appeared normal.

WO 01/59122 PCT/SG01/00017

32

EXAMPLE 2

GUS Expression Pattern

The Ds gene trap element insertion confers GUS reporter gene expression, hence it was possible to analyze the endogenous expression pattern of the gene by histochemical staining for GUS activity (See, Sundaresan et al., 1995). Gus expression commences in young buds at the tip of the gynoecium cylinder. Later, as it develops, the expression expands into the stigmatic papillae and the distal portion of the gynoecium. In mature flowers the whole gynoecium stains. After fertilization, in the silique, the expression was limited to the valve replum boundary being more intense at the distal and proximal part of the valve (Fig. 3).

EXAMPLE 3

Gene Analysis

To understand the nature of the defect that causes an indehiscent phenotype, further characterization of the gene was performed. Through Tail PCR, a fragment of genomic DNA flanking the Ds element was amplified (Parinov et al., 1999). A search of the Arabidopsis thaliana genomic database revealed that the flanking sequences were identical to the genomic sequences from chromosome 5, contained within BAC clone accession number AB020742. Gene specific primers were designed to amplify a portion of cDNA sequence from an Arabidopsis thaliana flower cDNA library (The cDNA clones were isolated from an Arabidopsis thaliana flower cDNA library, prepared from the ecotype Landsberg erecta. The cDNA library is available from the Arabidopsis Stock Center ABRC at Ohio State University, and had been constructed using the Stratagene Uni-ZAP XR vector system (Weigel et al., 1992). The library was screened according to the manufacturer's protocol). The PCR fragment was then used as a probe to screen the same library. The cDNA clone isolated from the screen was a length of 931 base pairs and is predicted to encode a 210 amino acid protein. Analysis of the cDNA sequence revealed a strong similarity between SGT10166 and proteins belonging to the basic helix loop helix (bHLH) class of transcription factors. Members of the bHLH family of proteins play an important role in transcriptional regulation in animals, plants and fungi. These proteins generally function as dimers with the HLH region being involved in the homo/heterodimerization process and the basic domains functions to bind the DNA. In plants, many bHLH domain proteins have been identified and implicated in different functions (Murre et al., 1989). For example, bHLH proteins regulate anthocyanin biosynthesis in maize (B-Peru and R/Lc genes) (Radicella et al., 1991; Ludwig et al., 1989), response to abscisic acid and dehydration in *Arabidopsis* (rd 22 BPI) (Abe et al., 1997), and the expression of seed storage proteins in *Phaseolus* (PG1) (Kawagoe and Murai, 1996).

The genomic sequence with exons and introns for SGT10166 is set forth in SEQ ID NO:3. The sequences for SEQ ID NO:3 are set forth in Table No. 1.

TABLE 1

Exons and Introns of the SGT10166 Gene

Exon/Intron	5' Nucleotide	3' Nucleotide
Exon 1	1007 (start codon)	1243
Intron 1	1244	1355
Exon 2	1356	1427
Intron 2	1428	1517
Exon 3	1518	1583
Intron 3	1584	1661
Exon 4	1662	1727
Intron 4	1728	1821
Exon 5	1822	2013 (stop codon)

EXAMPLE 4

Reversion Analysis

To confirm that the observed phenotype seen in SGT10166 was caused by the insertion of the Ds element, reversion analysis was performed (Yang et al., 1999). DNA sequencing of the Ds insertion site revealed that the Ds insertion had not resulted in a typical 8 bp target site duplication. The base pair changes present at the Ds insertion site are shown in Figure 5. The wildtype ALC sequence shown in Figure 5 (SEQ ID NO:8) corresponds to bases 331-352 of SEQ ID NO:1. The tagged site is shown as SEQ ID NOs:9 and 10 which are interrupted by the insert. Ds was remobilized by crossing to plants carrying the Ac transposase gene (Sundaresan et al.,

1995) and eight mutant plants were observed with revertant wild type sectors, that is, they had siliques which dehisced. Seeds from these revertants siliques were planted, DNA prepared and the sequence alterations expected from Ds excision were analyzed. All sequenced revertant genes contained an excised Ds element as evidenced by the absence of Ds sequences, and a 9 bp footprint at the same site. The footprint restores the reading frame and results in the addition of three extra amino acids to the original protein (Figure 5, bolded 9 bases of SEQ ID NO:11 shown as the revertant). This result confirms that mutation was caused by the insertion of the Ds in the SGT10166 locus. In addition a stable allele with a 10 bp footprint which does not restore the reading frame was also isolated and was designated as alc10 (Figure 5; SEQ ID NO:12). The alc10 plants remained indehiscent as expected.

EXAMPLE 5

Complementation Studies

To prove that the isolated cDNA sequence of SGT10166 is sufficient to confer dehiscence, we introduced the presumptive full length cDNA clone of SGT10166 under the control of CaMV 35S promoter into the mutant plants by *Agrobacterium* mediated transformation (Clough and Bent, 1998). Out of 15 independent transformants obtained, dehiscence was restored completely in 2 mutant plants. These results show that the sequence isolated is necessary and sufficient for fruit dehiscence.

EXAMPLE 6

Dominant Negative Studies.

Since SGT10166 gene encodes a myc-related bHLH domain protein, it is possible to make dominant negative regulators against it to alter the dehiscence process. As previously proposed in the application, we made such a dominant negative construct by deleting the basic domain of the SGT10166 gene and replacing it with acidic sequences (Krylov et al., 1997). Such a protein should act as a dominant negative regulator by sequestering the endogenous SGT10166 bHLH protein to form inactive dimers. This construct was made by deleting bases 290-340 of SEQ ID NO:1 (shown as SEQ ID NO:13) and replacing them with SEQ ID NO:14 to yield SEQ ID NO:15 which encodes SEQ ID NO:16. This construct was transformed into wild type *Arabidopsis* plants by *Agrobacterium* mediated transformation (Clough and Bent, 1998). We

were able to delay dehiscence considerably by up to two weeks in 2 out of 35 independent transformants obtained. This result could also be explained as the result of co-suppression mechanisms rather than the proposed dominant negative effects. Nevertheless, we have established that the SGT10166 gene can be used in transgenic plants to delay dehiscence. It should be similarly possible to engineer indehiscent or delayed dehiscence plants by reducing the activity of this gene using an anti-sense approach (Gray et al., 1992).

While the invention has been disclosed in this patent application by reference to the details of preferred embodiments of the invention, it is to be understood that the disclosure is intended in an illustrative rather than in a limiting sense, as it is contemplated that modifications will readily occur to those skilled in the art, within the spirit of the invention and the scope of the appended claims.

LIST OF REFERENCES

Abe K, et al. (1987). J. Biol. Chem. 262:16793-16797.

Abe H, et al. (1997). The Plant Cell 9:1859-1868.

Adang MJ, et al. (1993). Plant Molec. Biol. 21:11311145.

Anand R (1992). Techniques for the Analysis of Complex Genomes, (Academic Press).

Altschul SF, et al. (1990). J. Mol. Biol. 215:403-410.

Altschul SF, et al. (1997). Nucl. Acids Res. 25:3389-3402.

Apse MP, et al. (1999). Science 285:1256-1258.

Ausubel FM, et al. (1992). <u>Current Protocols in Molecular Biology</u>, (John Wiley & Sons, New York, NY).

Bambot SB, et al. (1993). PCR Methods and Applications 2:266-271.

Beachy et al. (1990). Ann. Rev. Phytopathol. 28:451.

Beaucage SL and Caruthers MH (1981). Tetra. Letts. 22:1859-1862.

Beetham PR (1999). Proc. Natl. Acad. Sci USA 96:8774-8778.

Biocomputing: Informatics and Genome Projects, Smith DW, ed., Academic Press, NY (1993).

Botella JR, et al. (1994). Plant Molec. Biol. 24:757-766.

Carillo H and Lipman D (1988). SIAM J. Applied Math. 48:1073.

Chaubet et al. (1987). Devel. Genet. 8:461-473.

Clough SJ and Bent AF (1998). Plant J. 16:735-743.

Compton J (1991). Nature 350:91-92.

Computational Molecular Biology, Lesk AM, ed., Oxford Univ. Press, NY (1988).

Computer Analysis of Sequence Data, Part I, Griffin AM and Griffin HG, eds., Humana Press, NJ (1994).

Coupe SA, et al. (1994). Plant Molecular Biology 24:223-227.

DeGreef, et al. (1989). Bio/Technology 7:61.

Deutscher M (1990). Meth. Enzymology 182:83-89 (Academic Press, San Diego, CA).

Elliot, et al. (1993). Plant Molec. Biol. 21:515.

Enhancers and Eukaryotic Gene Expression, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1983).

Evans, et al. (1983). Protoplasts Isolation and Culture, <u>Handbook of Plant Cell Cultures</u> 1: 124-176 (MacMillan Publishing Co., NY).

Fahy E, et al. (1991). PCR Methods Appl. 1:25-33.

Fiers W, et al. (1978). Nature 273:113-120.

Fisher DK, et al. (1993). Plant Physiol. 102:1045-1046.

Fraley RT, et al. (1983). Proc. Nat. Acad. Sci. USA 80:4803-4807.

Fromm M, et al. (1985). Proc. Nat. Acad. Sci. USA 82:5824-5828.

Geiser M, et al. (1986). Gene 48:109-118.

Gelvin S, et al. (eds.) (1990). <u>Plant Molecular Biology: Manual</u>, Kluwer Academic Press, Dordrecht, Netherlands

Glover D (1985). DNA Cloning, I and II (Oxford Press).

Gray J, et al. (1992). Plant Mol Bio. 19 (1): 69-87.

Griess EA, et al. (1994). Plant Physiol. 104:1467-1468.

Gu Q, et al. (1998). Development 125:1509.

Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, CA (1994).

Guilley H, et al. (1982). Cell 30:763-773 (1982).

Guthrie G and Fink GR (1991). Guide to Yeast Genetics and Molecular Biology (Academic Press).

Hayes JD, et al. (1992). Biochem. J. 285:173-180.

Hohn et al. (1982). Molecular Biology of Plant Tumors (Academic Press, NY), pp. 549-560.

Horsch et al. (1984). Science 233:496-498.

Huub et al. (1993). Plant Molec. Biol. 21:985.

Innis MA, et al. (1990). <u>PCR Protocols: A Guide to Methods and Applications</u> (Academic Press, San Diego, CA).

Jakoby WB and Pastan IH (eds.) (1979). <u>Cell Culture</u>. *Methods in Enzymology* Vol. 58 (Academic Press, Inc., Harcourt Brace Jovanovich (NY)).

Jaynes, et al. (1993). Plant Sci. 89:43.

Jones DA, et al. (1994). Science 266:789-793.

Kanehisa M (1984). Nucl. Acids Res. 12:203-213.

Kasuga M, et al. (1999). Nature Biotech. 17:287-291.

Kawagoe Y and Murai N (1996). Plant Sci. 116:47.

Kawalleck P, et al. (1993). Plant Mol. Biol. 21:673-684.

Kaye C, et al. (1998). Plant Physiol. 116:1367-1377.

Kempin SA, et al. (1997). Nature 389:802-803.

Klee, et al. (1987). Ann. Review of Plant Physiology 38:467-486.

Klein et al. (1987). Nature 327:70-73.

Knutzon DS, et al. (1992). Proc. Nat. Acad. Sci. USA 89:2624-2628.

Kramer KJ, et al. (1993). Insect Biochem. Mol. Biol. 23:691-701.

Krylov D, et al. (1997). Proc. Natl. Acad. Sci. USA 94:12274-12279.

Kubo T, et al. (1988). FEBS Lett. 241:119-125.

Kyte J and Doolittle RF (1982). J. Mol. Biol. 157:105-132.

Lamb CJ, et al. (1992). Bio/Technology 10:1436-1445.

Larsen PB, et al. (1998). Plant Physiol. 117: 9-18.

Longemann, et al. (1992). Bio/Technology 10:3305.

Ludwig SR, et al. (1989). Proc. Natl. Acad. Sci. USA 86:7092-7096.

Maniatis T, et al. (1982). Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).

Marshall, et al. (1992). Theor. Appl. Genet. 83:435.

Martin GB, et al. (1993). Science 262:1432-1436.

Matteucci MD and Caruthers MH (1981). J. Am. Chem. Soc. 103:3185.

Metzger D, et al. (1988). Nature 334:31-36.

Miki, et al. (1990). Theor. Appl. Genet. 80:449.

Miki, et al. (1993). "Procedures for Introducing Foreign DNA into Plants," in *Methods in Plant Molecular Biology and Biotechnology*, Glick et al. (eds.), CRC Press, pp. 67-88.

Mindrinos M, et al. (1994). Cell 78:1089-1099.

Mol JMN, et al. (1994). Post-transcriptional inhibition of gene expression: sense and antisense genes. In: J. Paszkowski (Ed.). *Homologous Recombination and Gene Silencing in Plants*. Kluwer Academic Publishers. Dordrecht, Netherlands. pp. 309-334.

Monsour, et al. (1988). Nature 336:348-352.

Murre C, et al. (1989). Cell 56:777-783.

Odell JT, et al. (1985). Nature 313:810-812.

Pang, et al. (1992). Gene 116:165.

Parinov S, et al. (1999). The Plant Cell 11:2263-2270.

Pen J, et al. (1992). Bio/Technology 10:292-296.

Pilon-Smits EAH, et al. (1998). J. Plant Physiol. 152:525-532.

Przibilla E, et al. (1991). Plant Cell 3:169-174.

Raboy, et al. (1990). Maydica 35:383.

Radicella JP, et al. (1991). Plant Mol. Biol. 17:127-130.

Reagan JD (1994). J. Biol. Chem. 269:9-12.

Sambrook J, et al. (1989). Molecular Cloning: A Laboratory Manual, 2nd Ed. (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).

Schafer HE, et al. (1998). Plant Mol. Biol. 37:87-97.

Scharf SJ, et al. (1986). Science 233:1076-1078.

Scopes R (1982). Protein Purification: Principles and Practice, (Springer-Verlag, NY).

Sequence Analysis in Molecular Biology, von Heinje G, Academic Press (1987).

Sequence Analysis Primer, Gribskov M and Devereux J, eds., M Stockton Press, NY (1991)

<u>Sequence Analysis Software Package of the Genetics Computer Group</u>, Univ. of Wisconsin Biotechnology Center, Madison, WI.

Sessions A (1999). Trends Plant Sci. 4:296-297.

Shiroza T, et al. (1988). J. Bacterial. 170:810-816.

Silflow, et al. (1987). Devel. Genet. 8:435-460.

Søgaard M, et al. (1993). J. Biol. Chem. 268:22480-22484.

Spargo CA, et al. (1996). Mol. Cell. Probes 10:247-256.

Steinmetz M, et al. (1985). Mol. Gen. Genet. 200:220-228.

Sumitani J, et al. (1993). Biosci. Biotechnol. Biochem. 57:1243-1248.

Sundaresan V, et al. (1995). Gene Dev. 9:1797-1810.

Tavladoraki P, et al. (1993). Nature 366:469-472.

Taylor LP and Jorgensen RA (1992). J. Hered. 83:11-17.

Taylor et al. (1994). Abstract #497, Seventh Int'l. Symposium on Molecular Plant-Microbe Interactions.

Toubart P, et al. (1992). Plant J. 2:367-373.

Van Damme EJ, et al. (1994). Plant Mol. Biol. 24:825-830.

Van Hartingsveldt W, et al. (1993). Gene 127:87-94.

Walker GT, et al. (1992). Nucl. Acids Res. 20:1691-1696.

Weissbach A and Weissbach H (eds.) 1986. Methods in Enzymology, Volume 118, Academic Press, Inc., Orlando, FL.

Wetmur JG and Davidson N (1968). J. Mol. Biol. 31:349-370.

Weigel D, et al. (1992). Cell 69:843-859.

Wosnick MA, et al. (1987). Gene 60:115-127.

Wu DY and Wallace RB (1989). Genomics 4:560-569.

Wu and Grossman (1987). Methods in Enzymology, Vol. 153, "Recombinant DNA Part D". Academic Press, NY.

Yang WC, et al. (1999). Genes and Dev. 13:2108-2117.

Zaitlin M, et al. (eds.) (1985). Biotechnology in Plant Science, Academic Press, Inc., Orlando, FL.

Patents and Patent Applications:

Hitzeman et al., EP 73,675A.

European application No. 0 242 246

European patent application No. 0 333 033

PCT Publication Number W0 90/12084

PCT Publication Number WO93/02197

PCT Publication Number WO 98/09521.

- U.S. Patent No. 4,554,101.
- U.S. Patent No. 4,683,195.
- U.S. Patent No. 4,683,202.
- U.S. Patent No. 4,769,061
- U.S. Patent No. 4,810,648
- U.S. Patent No. 4,940,835
- U.S. Patent No. 4,975,374
- U.S. Patent No. 5,106,739.
- U.S. Patent No. 5,266,361.
- U.S. Patent No. 5,268,526.
- U.S. Patent No. 5,270,184.
- U.S. Patent No. 5,290,294.
- U.S. Patent No. 5,322,938.
- U.S. Patent No. 5,409,818.
- U.S. Patent No. 5,436,146.
- U.S. Patent No. 5,455,166.
- U.S. Patent No. 5,607,914
- U.S. Patent No. 5,633,441.
- U.S. Patent No. 5,659,026
- U.S. Patent No. 5,691,198.
- U.S. Patent No. 5,710,267.
- U.S. Patent No. 5,735,500.
- U.S. Patent No. 5,747,469.
- U.S. Patent No. 5,850,020.

SEQUENCE LISTING

<110> Institute of Molecular Agrobiology
Sundaresan, Venkatesan
Sarojam, Rajani
<120> Dehiscence Gene and Methods for Regulating Dehiscence

<150> PCT/SG00/00022

<130> 2577-145.PCT

<151> 2000-02-11

<160> 16

<170> PatentIn version 3.0

<210> 1

<211> 931

<212> DNA

<213> Arabidopsis thaliana

<220>

<221> CDS

<222> (23)..(652)

Ala 75	Phe	Glu	His	Lys	Arg 80	Ser	Gly	Ala	Lys	Gln 85	Arg	Asn	Ser	Leu	Lys 90	
aga Arg	aac Asn	att Ile	gat Asp	gct Ala 95	caa Gln	ttc Phe	cac His	aac Asn	ttg Leu 100	tct Ser	gaa Glu	aag Lys	aag Lys	agg Arg 105	agg Arg	340
agc Ser	aag Lys	atc Ile	aac Asn 110	gag Glu	aaa Lys	atg Met	aaa Lys	gct Ala 115	ttg Leu	cag Gln	aaa Lys	ctc Leu	att Ile 120	ccc Pro	aat Asn	388
tcc Ser	aac Asn	aag Lys 125	act Thr	gat Asp	aaa Lys	gcc Ala	tca Ser 130	atg Met	ctt Leu	gat Asp	gaa Glu	gct Ala 135	ata Ile	gaa Glu	tat Tyr	436
ctg Leu	aag Lys 140	cag Gln	ctt Leu	caa Gln	ctt Leu	caa Gln 145	gtc Val	cag Gln	act Thr	tta Leu	gcc Ala 150	gtt Val	atg Met	aat Asn	ggt Gly	484
tta Leu 155	ggc Gly	tta Leu	aac Asn	cct Pro	atg Met 160	cga Arg	tta Leu	cca Pro	cag Gln	gtt Val 165	cca Pro	cct Pro	cca Pro	act Thr	cat His 170	532
aca Thr	agg Arg	atc Ile	aat Asn	gag Glu 175	acc Thr	tta Leu	gag Glu	caa Gln	gac Asp 180	ctg Leu	aac Asn	cta Leu	gag Glu	act Thr 185	ctt Leu	580
ctc Leu	gct Ala	gct Ala	cct Pro 190	cac His	tcg Ser	ctg Leu	gaa Glu	cca Pro 195	gct Ala	aaa Lys	aca Thr	agt Ser	caa Gln 200	gga Gly	atg Met	628
tgc Cys	ttt Phe	tcc Ser 205	aca Thr	gcc Ala	act Thr	ctg Leu	ctt Leu 210	tgaa	igata	ac a	ttca	ıgaca	ia to	jatga	tgat	682
cgga	atto	ct o	tagt	acct	g co	agac	agga	gtg	aaca	atg	tttt	gagt	tt t	agca	ttggc	742
caga	ittto	ta t	gtto	agtt	a ta	gtta	tgct	aat	aago	ttt	agga	gtga	ac, a	aaat	ctgag	802
tagi	ttga	att a	ataat	gate	jt ct	gaag	caga	ı tta	tata	taa	aaga	ctaa	itt t	actt	acata	862
tga	gatga	itt a	attac	aact	a to	aaat	gact	atç	tctg	tga	gtt	cato	ca a	aaaa	aaaaa	922
aaa	aaaa	aa														931

<210> 2

<211> 210

<212> PRT

<213> Arabidopsis thaliana

<400> 2

Met Gly Asp Ser Asp Val Gly Asp Arg Leu Pro Pro Pro Ser Ser Ser 1 5 10 15

Asp Glu Leu Ser Ser Phe Leu Arg Gln Ile Leu Ser Arg Thr Pro Thr 20 25 30

Ala Gln Pro Ser Ser Pro Pro Lys Ser Thr Asn Val Ser Ser Ala Glu 35 40 45

Thr Phe Phe Pro Ser Val Ser Gly Gly Ala Val Ser Ser Val Gly Tyr

50

55

Gly Val Ser Glu Thr Gly Gln Asp Lys Tyr Ala Phe Glu His Lys Arg

Ser Gly Ala Lys Gln Arg Asn Ser Leu Lys Arg Asn Ile Asp Ala Gln

Phe His Asn Leu Ser Glu Lys Lys Arg Arg Ser Lys Ile Asn Glu Lys

Met Lys Ala Leu Gln Lys Leu Ile Pro Asn Ser Asn Lys Thr Asp Lys

Ala Ser Met Leu Asp Glu Ala Ile Glu Tyr Leu Lys Gln Leu Gln Leu

Gln Val Gln Thr Leu Ala Val Met Asn Gly Leu Gly Leu Asn Pro Met

Arg Leu Pro Gln Val Pro Pro Pro Thr His Thr Arg Ile Asn Glu Thr

Leu Glu Gln Asp Leu Asn Leu Glu Thr Leu Leu Ala Ala Pro His Ser

Leu Glu Pro Ala Lys Thr Ser Gln Gly Met Cys Phe Ser Thr Ala Thr 205 200 195

Leu Leu 210

<210> 3

<211> 2640

<212> DNA

<213> Arabidopsis thaliana

<220>

<221> exon

<222> (1007)..(1243)

<223> Exon 1 not including sequence before the translation start site.

<220>

<221> Intron

<222> (1244)..(1355)

<223> Intron 1.

```
<220>
 <221> exon
 <222> (1356)..(1427)
 <223> Exon 2.
 <220>
 <221> Intron
 <222> (1428)..(1517)
 <223> Intron 2.
 <220>
 <221> exon
 <222> (1518)..(1583)
 <223> Exon 3.
 <220>
 <221> Intron
 <222> (1584)..(1661)
 <223> Intron 3.
 <220>
 <221> exon
 <222> (1662)..(1727)
 <223> Exon 4.
 <220>
 <221> Intron
 <222> (1728)..(1821)
 <223> Intron 4.
 <220>
 <221> exon
. <222> (1822)..(2013)
```

<223> Exon 5 through the stop codon. Exon 5 continues beyond this.

<400> 3 aattacaaaa tatttagaca	ataattcata aacatatcat	aaataagatc acattcataa	60
aataaatgag ttttttaga	ggacgggttg gcgggacggg	tttggcagga cgttacttaa	120
taacaattgt aaactataca	ataaaaatat tttatagata	gatacaattt acaaactttt	180
atatatatta atttaaaaaa	taaattgttt tcgcggtata	ccgcgggtta aaatctagtt	240
attcttattt ttgctatgaa	ccataattat tttaattact	atattatata tatttccctt	300
tggatgcatt aaaaaaaggc	taatgatcaa ggacatgtta	tcgtctttgt attgaccatt	360
ataatatctg aattttattt	tgtgttaaat aatctctcga	ataaataatc tttcgaaatg	420
catgcagttt tattcacact	ttatctgtgg acaacaacaa	caacaaaaaa gaaggaaaaa	480
atagattttt gtaatttgtc	aaaaatggtg aaactgttgc	gagaccttac ttttcaagta	540
attgtccatt ttcatgttta	gtcataataa taattaaata	gtctatcaat gctctatctt	600
atcaatactc ttatttttc	aaccgtttca tttactgatt	ttcataattt catcccctcc	660
tctcaattta acttatcaca	ttgaaaaaaa caataaaaat	gtatgttttt tatttacttg	720
gtggtccaaa aatgcttttt	tootttttt tattaggtaa	aaaatataat attattaaat	780
aaaattgcta caaaaggaaa	ctgttcacac acagagtgat	gtgagacacc agattctgtc	840
tatagggatt cgacacgcca	ctcgcctctt ttagaacctc	cacgcgcttc tctgaagaac	900
gtgatctcac gcgtcctacc	tccccgcct ataagcttta	ctacgaaaaa gccacagtga	960
taatttttac acacagagta	gagcagagag agagagagag	agagag atg ggt gat Met Gly Asp 1	1015
tct gac gtc ggt gat c Ser Asp Val Gly Asp A 5	gt ctt ccc cct cca tct rg Leu Pro Pro Pro Ser 10	tct tcc gac gaa ctc Ser Ser Asp Glu Leu 15	1063
Ser Ser Phe Leu Arg G	ag att ctt tcc cgt act in Ile Leu Ser Arg Thr 5 30	cct aca gct caa cct Pro Thr Ala Gln Pro 35	1111
tct tca cca ccg aag a Ser Ser Pro Pro Lys S 40	gt act aat gtt tcc tcc er Thr Asn Val Ser Ser 45	gct gag acc ttc ttc Ala Glu Thr Phe Phe 50	1159
cct tcc gtt tcc ggc g Pro Ser Val Ser Gly G 55	gga gct gtt tct tcc gtc ly Ala Val Ser Ser Val 60	ggt tat gga gtc tct Gly Tyr Gly Val Ser 65	1207
gaa act ggc caa gac a Glu Thr Gly Gln Asp I 70	aaa tat gct ttc gaa cac .ys Tyr Ala Phe Glu His 75	aag gtataaactt Lys	1253
aactattett agetgeagae	, atgetteact tggettteet	tgtaaaagaa aacaaaaacc	1313
	ttggaatggc taaacactaa	•	1367
aaa cag aga aat tcg t Lys Gln Arg Asn Ser I	tg aag aga aac att gat Leu Lys Arg Asn Ile Asp	gct caa ttc cac aac Ala Gln Phe His Asn	1415
85	90	95	
ttg tct gaa aag gtttt Leu Ser Glu Lys 100	cctctt ttatcttcct tttaa	gatto ttaatttaga	1467

aagaagaaga accttgagat tgtagttgat tagaatctga gtgttagcag aag agg Lys Arg 105	1523
agg agc aag atc aac gag aaa atg aaa gct ttg cag aaa ctc att ccc Arg Ser Lys Ile Asn Glu Lys Met Lys Ala Leu Gln Lys Leu Ile Pro 110 115	1571
aat too aac aag gttaatcaat otttgttoga atcagagata gtgagaaaca Asn Ser Asn Lys 125	1623
ttgttctgat tgatccgtta tcttttgttt gtttatag act gat aaa gcc tca atg Thr Asp Lys Ala Ser Met 130	1679
ctt gat gaa gct ata gaa tat ctg aag cag ctt caa ctt caa gtc cag Leu Asp Glu Ala Ile Glu Tyr Leu Lys Gln Leu Gln Leu Gln Val Gln 135	1727
gttttttcc tacttactat gattatatac gttcaaagtc tgatttgtaa attacatcac	1787
tcagatcatt aacttgattt actgcatgat gcag act tta gcc gtt atg aat ggt Thr Leu Ala Val Met Asn Gly 150	1842
tta ggc tta aac cct atg cga tta cca cag gtt cca cct cca act cat Leu Gly Leu Asn Pro Met Arg Leu Pro Gln Val Pro Pro Pro Thr His 155 160 165 170	1890
aca agg atc aat gag acc tta gag caa gac ctg aac cta gag act ctt Thr Arg Ile Asn Glu Thr Leu Glu Gln Asp Leu Asn Leu Glu Thr Leu 175 180 185	1938
ctc gct gct cct cac tcg ctg gaa cca gct aaa aca agt caa gga atg Leu Ala Ala Pro His Ser Leu Glu Pro Ala Lys Thr Ser Gln Gly Met 190 195 200	1986
tgc ttt tcc aca gcc act ctg ctt tga agataacatt cagacaatga Cys Phe Ser Thr Ala Thr Leu Leu 205 210	2033
tgatgatcgg aattcctcta gtacctgcca gacaggagtg aacaatgttt tgagttttag	2093
cattggccag atttctatgt tcagttatag ttatgctaat aagctttagg agtgaacaaa	2153
atctgagtag tttgattata atgatgtctg aagcagatta tatataaaag actaatttac	2213
ttacatatga gatgattatt acaactatca aatgactatg tctgtgagtt gcatccatcc	2273
ataagcacac cggtctctac tacttcgagt gattgctgct gctgacttaa ccgcaggtct	2333
tatcttcgtc attgctttct ctacttgaat tctcacgcca acatccatct gttatttcaa	2393
atggtaccga taactttagg gatatagaca agacaaattg atattaataa tataacaagg	2453
ttgtaaagta gaaacctttt ctaaagagca ttgtgtgtct aagatgtggc agaagtatga	2513
cagttgcttg tacaagtctg cttcagtgta ctgtaaagtc aagagttagt ctgtgaagca	2573
atagagagat aggagttata aggttgatga tggtatatac ctttcgtaag agggttccgt	2633
tacagtt	2640

<210> 4

<211> 623

<212> PRT

<213> Arabidopsis thaliana

<400> 4

Met Thr Asp Tyr Arg Leu Gln Pro Thr Met Asn Leu Trp Thr Thr Asp Asp Asn Ala Ser Met Met Glu Ala Phe Met Ser Ser Ser Asp Ile Ser Thr Leu Trp Pro Pro Ala Ser Thr Thr Thr Thr Thr Ala Thr Thr Glu Thr Thr Pro Thr Pro Ala Met Glu Ile Pro Ala Gln Ala Gly Phe Asn Gln Glu Thr Leu Gln Gln Arg Leu Gln Ala Leu Ile Glu Gly Thr His Glu Gly Trp Thr Tyr Ala Ile Phe Trp Gln Pro Ser Tyr Asp Phe Ser 85 90 95 Gly Ala Ser Val Leu Gly Trp Gly Asp Gly Tyr Tyr Lys Gly Glu Glu 100 105 110 Asp Lys Ala Asn Pro Arg Arg Arg Ser Ser Ser Pro Pro Phe Ser Thr Pro Ala Asp Gln Glu Tyr Arg Lys Lys Val Leu Arg Glu Leu Asn Ser 130 140 Leu Ile Ser Gly Gly Val Ala Pro Ser Asp Asp Ala Val Asp Glu Glu 145 150 155 160 Val Thr Asp Thr Glu Trp Phe Phe Leu Val Ser Met Thr Gln Ser Phe Ala Cys Gly Ala Gly Leu Ala Gly Lys Ala Phe Ala Thr Gly Asn Ala 180 185 190 Val Trp Val Ser Gly Ser Asp Gln Leu Ser Gly Ser Gly Cys Glu Arg 195 200 205 Ala Lys Gln Gly Gly Val Phe Gly Met His Thr Ile Ala Cys Ile Pro Ser Ala Asn Gly Val Val Glu Val Gly Ser Thr Glu Pro Ile Arg Gln Ser Ser Asp Leu Ile Asn Lys Val Arg Ile Leu Phe Asn Phe Asp Gly Gly Asp Gly Asp Leu Ser Gly Leu Asn Trp Asn Leu Asp Pro Asp Gln Gly Glu Asn Asp Pro Ser Met Trp Ile Asn Asp Pro Ile Gly Thr Pro Gly Ser Asn Glu Pro Gly Asn Gly Ala Pro Ser Ser Ser Gln Leu Phe Ser Lys Ser Ile Gln Phe Glu Asn Gly Ser Ser Ser Thr Ile Thr Glu Asn Pro Asn Leu Asp Pro Thr Pro Ser Pro Val His Ser Gln Thr Gln Asn Pro Lys Phe Asn Asn Thr Phe Ser Arg Glu Leu Asn Phe Ser Asp Val Lys Phe Tyr Phe Ser Glu Pro Arg Ser Gly Glu Ile Leu Asn

Phe Gly Asp Glu Gly Lys Arg Ser Ser Gly Asn Pro Asp Pro Ser Ser 370 380

Tyr Ser Gly Gln Thr Gln Phe Glu Asn Lys Arg Lys Arg Ser Met Val 385 390 395 400

Leu Asn Glu Asp Lys Val Leu Ser Phe Gly Asp Lys Thr Ala Gly Glu 405 410 415

Ser Asp His Ser Asp Leu Glu Ala Ser Val Val Lys Glu Val Ala Val 420 425 430

Glu Lys Arg Pro Lys Lys Arg Gly Arg Lys Pro Ala Asn Gly Arg Glu 435 440 445

Glu Pro Leu Asn His Val Glu Ala Glu Arg Gln Arg Arg Glu Lys Leu
450 460

Asn Gln Arg Phe Tyr Ala Leu Arg Ala Val Val Pro Asn Val Ser Lys 465 470 475 480

Met Asp Lys Ala Ser Leu Leu Gly Asp Ala Ile Ala Tyr Ile Asn Glu
485 490 495

Leu Lys Ser Lys Val Val Lys Thr Glu Ser Glu Lys Leu Gln Ile Lys 500 505 510

Asn Gln Leu Glu Glu Val Lys Leu Glu Leu Ala Gly Arg Lys Ala Ser 515 520 525

Pro Ser Gly Gly Asp Met Ser Ser Ser Cys Ser Ser Ile Lys Pro Val 530 535 540

Gly Met Glu Ile Glu Val Lys Ile Ile Gly Trp Asp Ala Met Ile Arg 545 550 560

Val Glu Ser Ser Lys Arg Asn His Pro Ala Ala Arg Leu Met Ser Ala 565 570 575

Leu Met Asp Leu Glu Leu Glu Val Asn His Ala Ser Met Ser Val Val 580 585

Asn Asp Leu Met Ile Gln Gln Ala Thr Val Lys Met Gly Phe Arg Ile 595 600 605

Tyr Thr Gln Asp Gln Leu Arg Ala Ser Leu Ile Ser Lys Ile Gly 610 615

<210> 5

<211> 642

<212> PRT

<213> Phaseolus vulgaris

<400> 5

Met Thr Glu Tyr Arg Ser Pro Pro Thr Met Asn Leu Trp Thr Asp Asp 1 5 10 15

Asn Ala Ser Val Met Glu Ala Phe Met Ser Ser Ser Asp Phe Ser Ser Ser 30

Leu Trp Leu Pro Thr Pro Gln Ser Ala Ala Ser Thr Thr Thr Pro Gly 35 40

Ala Asp Thr Ala Arg Ala Leu Pro Pro Pro Pro Pro Ser Gln Ser Gln 50 55

Ser Leu Phe Asn Gln Glu Thr Leu Gln Gln Arg Leu Gln Thr Leu Ile Glu Gly Ala Glu Glu Ser Trp Thr Tyr Ala Ile Phe Trp Gln Ser Ser Tyr Asp Tyr Ser Ser Ser Thr Ser Leu Leu Gly Trp Gly Asp Gly Tyr Tyr Lys Gly Glu Glu Asp Lys Gly Lys Gly Lys Ala Pro Lys Glu Met Ser Ser Ala Glu Gln Asp His Arg Lys Lys Val Leu Arg Glu Leu Asn Ser Leu Ile Ser Gly Pro Phe Arg Ser Ala Asp Asp Val Asp Glu Glu Val Ser Asp Thr Glu Trp Phe Phe Leu Val Ser Met Thr Gln Ser Phe Leu Ser Gly Ser Gly Leu Pro Gly Gln Ala Phe Leu Asn Ser Ser Pro Val Trp Val Ala Gly Ala Asp Arg Leu Ser Asp Ser Thr Ser Glu Arg Ala Arg Gln Gly Gln Val Phe Gly Val Gln Thr Leu Val Cys Ile Pro Ser Ala Asn Gly Val Val Glu Leu Ala Ser Thr Glu Val Ile Phe Gln Asn Ser Asp Leu Met Lys Lys Val Arg Asp Leu Phe Asn Phe Asn Asn Pro Asp Ala Gly Phe Trp Pro Leu Asn Gln Gly Glu Asn Asp Pro Ser Ser Leu Trp Leu Asn Pro Ser Ser Ser Ile Glu Ile Lys Asp Thr Ser Asn Ala Val Ala Leu Val Ser Ala Asn Ala Ser Leu Ser Lys Thr Met Pro Phe Glu Thr Pro Gly Ser Ser Thr Leu Thr Glu Thr Pro Ser Ala Ala Ala Ala His Val Pro Asn Pro Lys Asn Gln Gly Phe Pro 325 330 335 Arg Glu Leu Asn Phe Ser Asn Ser Leu Lys Pro Glu Ser Gly Glu Ile Leu Ser Phe Gly Glu Ser Lys Lys Ser Ser Tyr Asn Gly Ser Tyr Phe 355 360 365 Pro Gly Val Ala Ala Glu Glu Thr Asn Lys Lys Arg Arg Ser Pro Ala Ser Arg Ser Ser Ile Asp Asp Gly Met Leu Ser Phe Thr Ser Gly Val 385 390 395 Ile Ile Pro Ala Ser Asn Ile Lys Ser Gly Ala Val Ala Gly Gly 415 Ala Ser Gly Gly Asp Ser Glu Asn Ser Asp Leu Glu Ala Ser Val Val Lys Glu Ala Asp Ser Arg Val Val Glu Pro Glu Lys Arg Pro Arg Lys

Arg Gly Arg Lys Pro Gly Asn Gly Arg Glu Glu Pro Leu Asn His Val 455 Glu Ala Glu Arg Gln Arg Arg Glu Lys Leu Asn Gln Arg Phe Tyr Ala 465 470 475 480 Leu Arg Ala Val Val Pro Asn Val Ser Lys Met Asp Lys Ala Ser Leu 490 Leu Gly Asp Ala Ile Ser Tyr Ile Asn Glu Leu Lys Ser Lys Leu Ser Glu Leu Glu Ser Glu Lys Gly Glu Leu Glu Lys Gln Leu Glu Leu Val Lys Lys Glu Leu Glu Leu Ala Thr Lys Ser Pro Ser Pro Pro Pro Gly Pro Pro Pro Ser Asn Lys Glu Ala Lys Glu Thr Thr Ser Lys Leu Ile Asp Leu Glu Leu Glu Val Lys Ile Ile Gly Trp Asp Ala Met Ile Arg Ile Gln Cys Ser Lys Lys Asn His Pro Ala Ala Arg Leu Met Ala Ala Leu Lys Glu Leu Asp Leu Asp Val Asn His Ala Ser Val Ser Val Val 600 Asn Asp Leu Met Ile Gln Gln Ala Thr Val Asn Met Gly Asn Arg Phe 615 Tyr Thr Gln Glu Gln Leu Arg Ser Ala Arg Ser Ser Lys Ile Gly Asn 625 630 635 Ala Leu <210> 6

<211> 610

<212> PRT

<213> Zea mays

<400> 6

Met Ala Leu Ser Ala Ser Arg Val Gln Gln Ala Glu Glu Leu Leu Gln 10 15 Arg Pro Ala Glu Arg Gln Leu Met Arg Ser Gln Leu Ala Ala Ala Ala 20 30

Arg Ser Ile Asn Trp Ser Tyr Ala Leu Phe Trp Ser Ile Ser Asp Thr

Gln Pro Gly Val Leu Thr Trp Thr Asp Gly Phe Tyr Asn Gly Glu Val 50 60

Lys Thr Arg Lys Ile Ser Asn Ser Val Glu Leu Thr Ser Asp Gln Leu 65 70 80

Val Met Gln Arg Ser Asp Gln Leu Arg Glu Leu Tyr Glu Ala Leu Leu 85 90 95

Ser Gly Glu Gly Asp Arg Arg Ala Ala Pro Ala Arg Pro Ala Gly Ser 100 105 110

Leu Ser Pro Glu Asp Leu Gly Asp Thr Glu Trp Tyr Tyr Val Val Ser

WO 01/59122 PCT/SG01/00017

125 120 115 Met Thr Tyr Ala Phe Arg Pro Gly Gln Gly Leu Pro Gly Arg Ser Phe Ala Ser Asp Glu His Val Trp Leu Cys Asn Ala His Leu Ala Gly Ser 145 150 155 160 Lys Ala Phe Pro Arg Ala Leu Leu Ala Lys Ser Ala Ser Ile Gln Ser 165 170 175 Ile Leu Cys Ile Pro Val Met Gly Gly Val Leu Glu Leu Gly Thr Thr 180 185 190 Asp Thr Val Pro Glu Ala Pro Asp Leu Val Ser Arg Ala Thr Ala Ala Phe Trp Glu Pro Gln Cys Pro Ser Ser Ser Pro Ser Gly Arg Ala Asn 210 215 Glu Thr Gly Glu Ala Ala Asp Asp Gly Thr Phe Ala Phe Glu Glu Leu Asp His Asn Asn Gly Met Asp Asp Ile Glu Ala Met Thr Ala Ala Gly Gly His Gly Gln Glu Glu Leu Arg Leu Arg Glu Ala Glu Ala 260 265 270 Leu Ser Asp Asp Ala Ser Leu Glu His Ile Thr Lys Glu Ile Glu Glu 275 280 285 Phe Tyr Ser Leu Cys Asp Glu Met Asp Leu Gln Ala Leu Pro Leu Pro Leu Glu Asp Gly Trp Thr Val Asp Ala Ser Asn Phe Glu Val Pro Cys Ser Ser Pro Gln Pro Ala Pro Pro Pro Val Asp Arg Ala Thr Ala Asn Val Ala Ala Asp Ala Ser Arg Ala Pro Val Tyr Gly Ser Arg Ala Thr Ser Phe Met Ala Trp Thr Arg Ser Ser Gln Gln Ser Ser Cys Ser Asp Asp Ala Ala Pro Ala Ala Val Pro Ala Ile Glu Glu Pro Gln Arg Leu Leu Lys Lys Val Val Ala Gly Gly Gly Ala Trp Glu Ser Cys Gly Gly Ala Thr Gly Ala Ala Gln Glu Met Ser Gly Thr Gly Thr Lys Asn His Val Met Ser Glu Arg Lys Arg Glu Lys Leu Asn Glu Met Phe 420 425 430 Leu Val Leu Lys Ser Leu Leu Pro Ser Ile His Arg Val Asn Lys Ala Ser Ile Leu Ala Glu Thr Ile Ala Tyr Leu Lys Glu Leu Gln Arg Arg Val Gln Glu Leu Glu Ser Ser Arg Glu Pro Ala Ser Arg Pro Ser Glu Thr Thr Thr Arg Leu Ile Thr Arg Pro Ser Arg Gly Asn Asn Glu Ser 490 Val Arg Lys Glu Val Cys Ala Gly Ser Lys Arg Lys Ser Pro Glu Leu 500 505 510

Gly Arg Asp Asp Val Glu Arg Pro Pro Val Leu Thr Met Asp Ala Gly 515 520 525

Thr Ser Asn Val Thr Val Thr Val Ser Asp Lys Asp Val Leu Leu Glu 530 540

Val Gln Cys Arg Trp Glu Glu Leu Leu Met Thr Arg Val Phe Asp Ala 545 550 560

Ile Lys Ser Leu His Leu Asp Val Leu Ser Val Gln Ala Ser Ala Pro 565 570 575

Asp Gly Phe Met Gly Leu Lys Ile Arg Ala Gln Phe Ala Gly Ser Gly 580 585 590

Ala Val Val Pro Trp Met Ile Ser Glu Ala Leu Arg Lys Ala Ile Gly 595 600 605

Lys Arg 610

<210> 7

<211> 562

<212> PRT

<213> Zea mays

<400> 7

Met Ala Leu Ser Ala Ser Pro Ala Gln Glu Glu Leu Leu Gln Pro Ala 1 5 10 15

Gly Arg Pro Leu Arg Lys Gln Leu Ala Ala Ala Ala Arg Ser Ile Asn 20 25 30

Trp Ser Tyr Ala Leu Phe Trp Ser Ile Ser Ser Thr Gln Arg Pro Arg 35 40 45

Val Leu Thr Trp Thr Asp Gly Phe Tyr Asn Gly Glu Val Lys Thr Arg
50 55 60

Lys Ile Ser His Ser Val Glu Leu Thr Ala Asp Gln Leu Leu Met Gln 65 70 75 80

Arg Ser Glu Gln Leu Arg Glu Leu Tyr Glu Ala Leu Arg Ser Gly Glu 85 90 95

Cys Asp Arg Arg Gly Ala Arg Pro Val Gly Ser Leu Ser Pro Glu Asp

Leu Gly Asp Thr Glu Trp Tyr Tyr Val Ile Cys Met Thr Tyr Ala Phe 115 120 125

Leu Pro Gly Gln Gly Leu Pro Gly Arg Ser Ser Ala Ser Asn Glu His
130 135 140

Val Trp Leu Cys Asn Ala His Leu Ala Gly Ser Lys Asp Phe Pro Arg 145 150 155 160

Ala Leu Leu Ala Lys Ser Ala Ser Ile Gln Thr Ile Val Cys Ile Pro 165 170 175

Leu Met Gly Gly Val Leu Glu Leu Gly Thr Thr Asp Lys Val Pro Glu

Asp Pro Asp Leu Val Ser Arg Ala Thr Val Ala Phe Trp Glu Pro Gln 195 200 205

Cys Pro Thr Tyr Ser Lys Glu Pro Ser Ser Asn Pro Ser Ala Tyr Glu 215 Thr Gly Glu Ala Ala Tyr Ile Val Val Leu Glu Asp Leu Asp His Asn Ala Met Asp Met Glu Thr Val Thr Ala Ala Ala Gly Arg His Gly Thr Gly Gln Glu Leu Gly Glu Val Glu Ser Pro Ser Asn Ala Ser Leu Glu His Ile Thr Lys Gly Ile Asp Glu Phe Tyr Ser Leu Cys Glu Glu Met Asp Val Gln Pro Leu Glu Asp Ala Trp Ile Met Asp Gly Ser Asn Phe Glu Val Pro Ser Ser Ala Leu Pro Val Asp Gly Ser Ser Ala Pro Ala 305 310 315 320 Asp Gly Ser Arg Ala Thr Ser Phe Val Val Trp Thr Arg Ser Ser His Ser Cys Ser Gly Glu Ala Ala Val Pro Val Ile Glu Glu Pro Gln Lys Cys Gly Gly Gly Thr Thr Val Thr Ala Gln Glu Asn Gly Ala Lys Asn His Val Met Ser Glu Arg Lys Arg Arg Glu Lys Leu Asn Glu Met 385 390 395 Phe Leu Val Leu Lys Ser Leu Val Pro Ser Ile His Lys Val Asp Lys Ala Ser Ile Leu Ala Glu Thr Ile Ala Tyr Leu Lys Glu Leu Gln Arg Arg Val Gln Glu Leu Glu Ser Arg Arg Gln Gly Gly Ser Gly Cys Val 435 440 445 Ser Lys Lys Val Cys Val Gly Ser Asn Ser Lys Arg Lys Ser Pro Glu 450 455 460 Phe Ala Gly Gly Ala Lys Glu His Pro Trp Val Leu Pro Met Asp Gly Thr Ser Asn Val Thr Val Thr Val Ser Asp Thr Asn Val Leu Leu Glu Val Gln Cys Arg Trp Glu Lys Leu Leu Met Thr Arg Val Phe Asp Ala Ile Lys Ser Leu His Leu Asp Ala Leu Ser Val Gln Ala Ser Ala Pro Asp Gly Phe Met Arg Leu Lys Ile Gly Ala Gln Phe Ala Gly Ser Gly Ala Val Val Pro Gly Met Ile Ser Gln Ser Leu Arg Lys Ala Ile Gly Lys Arg

<212> DNA

<400> aagaga	13 aaaca t	tgatgo	tca at	tccacaa	c ttg	tctgaaa	agaag	laggag (₹		51
<210>	14										
<211>	24										
<212>	DNA										
<213>	Arabi	dopsis.	thali	.ana							
<400> gaagaq	14 ggaag a	ıcgatga	laga gg	at							24
<210>	15										
<211>	904										
<212>	DNA										
<213>	Arabi	dopsis	thali	.ana							
							•				
<220>											
<221>											
<222>	(23).	.(625)	1								
-100>	15										
<400> agaga	15 gagag a	agagaga	igag aç	g atg gg Met Gl l	t gat y Asp	tct ga Ser As 5	c gtc p Val	ggt gat Gly Ası	cgt Arg	ctt Leu 10	52
agaga	gagag a	tct to	ct tcc er Ser	Met Gl	y Asp ctc Leu	Ser As	p vai	tc cga	cag	10 att	52 100
ccc cc Pro P:	gagag a	tct tc Ser Se 15	ct tcc er Ser	Met Gl	y Asp ctc Leu cct	tcg agc Ser Ser 20	ttt c Phe L	ctc cga eu Arg	cag Gln 25	10 att Ile	
ccc cc Pro P:	ct cca ro Pro cc cgt er Arg	tct tc Ser Se 15 act cc Thr Pr	et tcc er Ser ot aca co Thr	Met Gl l gac gaa Asp Glu	ctc Leu cct Pro 35	tcg agc Ser Ser 20 tct tca Ser Ser	ttt c Phe L cca c Pro P gtt t Val S	etc cga eu Arg ccg aag ro Lys 40	cag Gln 25 agt Ser	10 att Ile act Thr	100
ccc cc Pro P: ctt tc Leu S: aat g Asn V	ct cca ro Pro cc cgt er Arg	tot to Ser Ser 15 act co Thr Pr 30 tcc go Ser Al	et tcc er Ser oct aca co Thr et gag la Glu	Met Gl l gac gaa Asp Glu gct caa Ala Gln acc ttc Thr Phe	ctc Leu cct Pro 35 ttc Phe	tcg agc Ser Ser 20 tct tca Ser Ser cct tcc Pro Ser	ttt c Phe L cca c Pro P gtt t Val S	etc cga eu Arg ccg aag Pro Lys 40 ccc ggc eer Gly	cag Gln 25 agt Ser gga Gly	att Ile act Thr gct Ala	100
ccc cc Pro P: ctt tc Leu S: aat g Asn V	ct cca ro Pro cc cgt er Arg tt tcc 'al Ser 45	tet tet te Ser Se 15 act co Thr Pr 30 tec go Ser Al	et tcc er Ser ot aca co Thr et gag la Glu gt tat ly Tyr	met Gl 1 gac gaa Asp Glu gct caa Ala Gln acc ttc Thr Phe 50 gga gtc Gly Val	ctc Leu cct Pro 35 ttc Phe tct Ser	tcg agc Ser Ser 20 tct tca Ser Ser cct tcc Pro Ser gaa act Glu Thr	ttt c Phe L cca c Pro P gtt t Val S ggc c Gly G 70	cc gac Gly as gac	cag Gln 25 agt Ser gga Gly aaa Lys	att Ile act Thr gct Ala tat Tyr	100 148 196
agagad ccc cc Pro P: ctt tc Leu Sc aat gr Asn V. gtt t. Val Sc gct t Ala P 75	ct cca ro Pro cc cgt er Arg tt tcc al Ser 45 ct tcc er Ser 0	tot to Ser Ser Ser 15 act co Thr Pr 30 tcc go Ser Al gtc go Val Gi	et tcc er Ser et aca co Thr et gag la Glu gt tat ly Tyr ag aga ys Arg 80	Met Gl 1 gac gaa Asp Glu gct caa Ala Gln acc ttc Thr Phe 50 gga gtc Gly Val 65	ctc Leu cct Pro 35 ttc Phe tct Ser gct Ala	tcg agc Ser Ser 20 tct tca Ser Ser cct tcc Pro Ser gaa act Glu Thr aaa cag Lys Gln 85 atc aac	ttt CPhe L cca CPro P gtt ts Val S5 ggc CGly G 70 aga a Arg A	ttc cga eu Arg cg aag ro Lys 40 ccc ggc er Gly 55 caa gac cln Asp	cag Gln 25 agt Ser gga Gly aaa Lys ttg Leu	att Ile act Thr gct Ala tat Tyr gaa Glu 90 gct	100 148 196 244
agagad CCC CPro P: Ctt tt Leu Schaff V. gtt tval Schaff Color CPro P: gag gg Glu G	ct cca ro Pro cc cgt er Arg tt tcc al Ser 45 ct tcc er Ser 0 tc gaa he Glu	tct tc Ser Ser Ser 15 act cc Thr Pr 30 tcc gc Ser Al gtc gc Val G. cac aa His Ly	et tcc er Ser et aca co Thr et gag la Glu gt tat Ly Tyr ag aga ays Arg 80 aa gag lu Glu	met Gl 1 gac gaa Asp Glu gct caa Ala Gln acc ttc Thr Phe 50 gga gtc Gly Val 65 agt gga Ser Gly	ctc Leu cct Pro 35 ttc Phe tct Ser gct Ala aag	tcg agc Ser Ser 20 tct tca Ser Ser Cct tcc Pro Ser Glu Thr aaa cag Lys Gln 85 atc aac Ile Asn	ttt CPhe I cca CPro P gtt tval S ggc Gly G Gly G aga a Arg A gag a Glu I	tc cga eu Arg cg aag ro Lys 40 cc ggc er Gly saa gac en Asp aat tcg asn Ser aaa atg	cag Gln 25 agt Ser gga Gly aaa Lys ttg Leu	att Ile act Thr gct Ala tat Tyr gaa Glu 90 gct Ala	100 148 196 244

WO 01/59122 PCT/SG01/00017

ctt Leu	gat Asp	gaa Glu 125	gct Ala	ata Ile	gaa Glu	tat Tyr	ctg Leu 130	aag Lys	cag Gln	ctt Leu	caa Gln	ctt Leu 135	caa Gln	gtc Val	cag Gln	436
act Thr	tta Leu 140	gcc Ala	gtt Val	atg Met	aat Asn	ggt Gly 145	tta Leu	ggc Gly	tta Leu	aac Asn	cct Pro 150	atg Met	cga Arg	tta Leu	cca Pro	484
cag Gln 155	gtt Val	cca Pro	cct Pro	cca Pro	act Thr 160	cat His	aca Thr	agg Arg	atc Ile	aat Asn 165	gag Glu	acc Thr	tta Leu	gag Glu	caa Gln 170	532
gac Asp	ctg Leu	aac Asn	cta Leu	gag Glu 175	act Thr	ctt Leu	ctc Leu	gct Ala	gct Ala 180	cct Pro	cac His	tcg Ser	ctg Leu	gaa Glu 185	cca Pro	580
gct Ala	aaa Lys	aca Thr	agt Ser 190	caa Gln	gga Gly	atg Met	tgc Cys	ttt Phe 195	tcc Ser	aca Thr	gcc Ala	act Thr	ctg Leu 200	ctt Leu		625
tgaa	igata	ac a	ittca	ıgaca	a to	gatga	tgat	. cgg	jaatt	cct	ctag	tacc	tg o	caga	cagga	685
gtga	acaa	atg t	tttg	gagtt	t ta	gcat	tggc	caç	attt	cta	tgtt	cagt	ta t	agtt	atgct	745
aata	agct	tt a	aggag	jtgaa	c aa	aato	tgaç	tag	ıtttç	att	ataa	tgat	gt o	tgaa	igcaga	805
ttat	atat	aa a	agac	taat	t ta	ctta	cata	tga	gatg	att	atta	caac	ta t	caaa	tgact	865
atgt	ctgt	ga	jttgo	atco	a aa	aaaa	aaaa	aaa	aaaa	ıaa					•	904

<210> 16

<211> 201

<212> PRT

<213> Arabidopsis thaliana

<400> 16

Met Gly Asp Ser Asp Val Gly Asp Arg Leu Pro Pro Pro Ser Ser Ser 1 5 10 15

Asp Glu Leu Ser Ser Phe Leu Arg Gln Ile Leu Ser Arg Thr Pro Thr 20 25 30

Ala Gln Pro Ser Ser Pro Pro Lys Ser Thr Asn Val Ser Ser Ala Glu 35 40 45

Thr Phe Phe Pro Ser Val Ser Gly Gly Ala Val Ser Ser Val Gly Tyr 50 55 60

Gly Val Ser Glu Thr Gly Gln Asp Lys Tyr Ala Phe Glu His Lys Arg 70 75 80

Ser Gly Ala Lys Gln Arg Asn Ser Leu Glu Glu Glu Asp Asp Glu Glu 85 90 95

Asp Ser Lys Ile Asn Glu Lys Met Lys Ala Leu Gln Lys Leu Ile Pro 100 105 110

Asn Ser Asn Lys Thr Asp Lys Ala Ser Met Leu Asp Glu Ala Ile Glu 115 120 125

Tyr Leu Lys Gln Leu Gln Leu Gln Val Gln Thr Leu Ala Val Met Asn 130 135 140

Gly Leu Gly Leu Asn Pro Met Arg Leu Pro Gln Val Pro Pro Pro Thr 145 150 150 160

His Thr Arg Ile Asn Glu Thr Leu Glu Gln Asp Leu Asn Leu Glu Thr 165 170 175

Leu Leu Ala Ala Pro His Ser Leu Glu Pro Ala Lys Thr Ser Gln Gly 180 185 190

Met Cys Phe Ser Thr Ala Thr Leu Leu 195 200

WHAT IS CLAIMED IS:

- An isolated DNA comprising a nucleic acid or its complement, said nucleic acid comprises a nucleotide sequence coding for (a) SGT10166 comprising an amino acid sequence set forth in SEQ ID NO:2 or (b) a protein comprising an amino acid sequence that has at least 90% identity with an amino acid sequence set forth in said SEQ ID NO:2.
- The isolated DNA of claim 1, wherein said nucleic acid comprises (a) a nucleotide sequence set forth in SEQ ID NO:1 or its complement or (b) a nucleotide sequence comprising nucleotides 23-654 set forth in SEQ ID NO:1 or its complement.
- 3. The isolated DNA of claim 1 or 2, wherein said nucleic acid comprises a nucleotide sequence that has at least 90% identity with (a) a nucleotide sequence set forth in SEQ ID NO:1 or its complement or (b) a nucleotide sequence comprising nucleotides 23-654 set forth in SEQ ID NO:1 or its complement.
- 4. An isolated DNA comprising a nucleic acid or its complement which comprises a nucleotide sequence coding for a mutated SGT10116 protein compared to a wild-type SGT10166 protein comprising an amino acid sequence set forth in SEQ ID NO:2, wherein said mutated SGT10116 protein causes an indehiscence phenotype.
- 5. An isolated DNA comprising a nucleic acid which comprises an SGT10166 regulatory sequence.
- 6. The isolated DNA of claim 5, wherein said nucleic acid comprises an SGT10166 intron.
- 7. The isolated DNA of claim 5 or 6, wherein said nucleic acid comprises a nucleotide sequence comprising nucleotides 260-371 of SEQ ID NO:3 or its complement or fragment thereof which provides fruit tissue specificity.

- 8. The isolated DNA of any one of claims 5 to 7, wherein said nucleic acid comprises an SGT10166 promoter.
- 9. The isolated DNA of any one of claims 5 to 8, wherein said nucleic acid comprises an SGT10166 termination sequence.
- 10. A DNA molecule comprising a first nucleic acid comprising a heterologous promoter operably linked to the isolated DNA of any one of the preceding claims or a fragment thereof which is capable of altering dehiscence of a mature fruit in plants.
- 11. The DNA molecule of claim 10, wherein said dehiscence is altered by an antisense mechanism.
- 12. The DNA molecule of claim 10 or 11, wherein said dehiscence is altered by a sense suppression mechanism.
- 13. A vector comprising the isolated DNA of any one of claims 1 to 9.
- 14. A transformed plant cell comprising the isolated DNA of any one of claims 1 to 9 or a fragment thereof which is capable of altering dehiscence of a mature fruit in plants.
- 15. A transformed plant comprising the isolated DNA of any one of claims 1 to 9, or fragment thereof which is capable of altering dehiscence of a mature fruit in plants.
- 16. A transformed plant comprising the DNA molecule of any one of claims 10 to 12 or fragment thereof which is capable of altering dehiscence of a mature fruit in plants.
- 17. The transformed plant of claim 15 or 16, which is a plant which produces seed pods.

- 18. The transformed plant of claim 15, 16 or 17, further comprising a nucleic acid which comprises an inducible promoter operably linked to a third nucleotide sequence encoding a means of inactivating a lethal gene or its product.
- An isolated polypeptide selected comprising an amino acid sequence set forth in SEQ ID NO:2.
- 20. A method for producing indehiscent transgenic plants comprising transforming the plant cells with the DNA molecule of any one of claims 10 to 12, selecting transformed plant cells containing said DNA molecule and regenerating said indehiscent transgenic plant(s) from said transformed plant cells.
- 21. A DNA molecule comprising a first nucleic acid comprising the isolated DNA of any one of claims 1 to 9 operably linked to a second, heterologous nucleic acid.
- 22. The DNA molecule of claim 21, wherein said second nucleic acid is antisense DNA.
- 23. The DNA molecule of claim 22 or 23, wherein said second nucleic acid is capable of conferring a selected agronomic trait to a plant.
- 24. A vector comprising the DNA molecule of any one of claims 10 to 12 and 21 to 23.
- 25. A transformed plant cell comprising the isolated DNA of any one of claims 1 to 9.
- 26. A transformed plant cell comprising the DNA molecule of any one of claims 10 to 12 and 21 to 23.
- 27. A transformed plant comprising the isolated DNA of any one of claims 1 to 9.

WO 01/59122 PCT/SG01/00017

61

28. A transformed plant comprising the DNA molecule of any one of claims 10 to 12 and 21 to 23.




FIG. 1

2/8




FIG. 2




FIG. 3A FIG. 3B

AGAG!	\C\(\)	מאב	ACD(BAG	AGA(7AGZ	\TG(GGT	GAT	TCT	GAC	GTC	GGT	GAT	CGT	CTT	CCC	CCT	CC	60
							M	G	Ď	S	D	V	G	D	R	Η	Ъ	Р	P	
ATCT:	יירטיי	דרר	אר(3AA	CTC	rcg <i>i</i>	AGC'	TTT	CTC	CGA	CAG	TTA	CTT'	TCC	CGT	ACT	CCT	ACA(ЭC	120
S	S	S	D	Ε	L	S	S	F	L	R	Q	I	L	S	R	T	P	Т	A	
TCAA	ىلىك	ىلىن	ኮሮኔ፣	מרש.	כרק	AAGI	ኒርጥ	ACT	AAT	GTT	TCC	TCC	GCT	GAG.	ACC'	TTC'	TTC	CCT'	ГC	180
Q		S				K	S	T	N	V	S	S	A	E	T	F	F	P	S	
CGTT'	דיריר	aac	2C	ترسب	יידיים	ηCηr	רככ	GTC	GGT	TAT	GGA	.GTC	TCT	GAA	ACT	GGC	CAA	GAC.	AA	240
V	S	G	G	A	V	S	S	V	G	Y	G	V	S	Ε	T	G	Q	ע	K	
ATAT	ረረጥ	ጥጥር	מממ		AAG.	AGA:	AGT	'GGA	GCT	'AAA'	CAG	AGA	AAT	TCG	TTG.	AAG	AGA	AAC.	ΤA	300
Y	A	F	Ε	Н	K	R	S	G	A	K	Q	R	N	S	П	K	ĸ	N	1	
TGAT	ርርጥ	רא אי	ጥጥር	CAC	ממכ	ጥጥር።	тст	'GAA	AAG	AAG	AGG	AGG	AGC	AAG	ATC	AAC	GAG	AAA	ΤA	360
D	A	Q	F	Н	N	L	S	Ε	K	K	R	R	S	K	1	N	E	K	IvI	
GAAA	CCT	تاشش	CZG	מממ	בידיכי	ΔTT	CCC	'AA'	TCC	'AAC	'AAC	ACT	GAT	'AAA'	.GCC	TCA	ATG	CTT	GA	420
K	A	L	Q	K	L	I	P	N	S	N	K	T	נו	K	A	5	141	'n	ע	
TGAA	מריז	מידמי	GAA	דביד.	'CTG	AAG	CAC	CTI	CA	ACTI	CAP	AGTO	CAG	ACT	ATT	.GCC	GTT:	'ATG	AA	480
E	A	I	Ε	Y	Γ	K	Q	L	Q	L	Q	V	Q	Т	L	А	V	ĬΛĬ	IA	
TGGT	ጥጥጀ	KGG('TTA	AAC	CCT	ATG	CGI	ATTA	ACCA	ACA(GT?	rcca	ACCI	CCP	ACT	'CA'I	ACA	AGG	AT	540
G	L	G	L	N	P	M	R	L	P	Q	V	Ъ	P	Р	Т	n	1	Л	1	
CAAT	יכאכ	:ACC	<u>ל</u> ידיי	GAC	CAA	GAC	CTC	GAA(CCT	AGA(GAC.	rcT7	rct(CGCI	GCI	CC1	CAC	TCG	CT	600
N	Ε	T	L	Ε	Q	D	L	N	L	Ε	Т	L	Ч	Α	Α	P	п	3	ם	
GGA	ייי	ላርርባ	בבבי	ACA	AAGT	CAA	.GGI	TAA	GTG(CTT:	TTC(CACA	AGC(CACI	CTC	CTT	TGP	AGA	ATA	660
Ε	P	A	K	Т	S	Q	G	M	С	F	S	T	А	1	L	ш	•			
ACA:	rtc <i>i</i>	AGAC	CAAT	[GA]	[GA]	rgat	CG(GAA'	rtc	CTC'	TAG'	TAC(CTG(CCAC	GACA	AGGI	AGTO	SAAC	'AA	720
TGT	rtt(GAGT	TTT	rag(CAT	rggo	CA	GAT'	TTC'	TAT	GTT(CAG'	TTA	TAG:	TAT	rgc'.	CAAT	PAAC	CT	780
TTA	GGA(GTG	AAC!	\AA!	ATC:	rga(ATE	GTT'	TGA	TTA'	TAA'	TGA'	TGT(CTG	AAG	CAG	ATTA	ATAI	TAT	840
AAA	AGA	CTA	ATT:	TAC'	TTA(CATA	ATG.	AGA'	TGA	TTA	TTA	CAA	CTA'	TCA	TAA	GAC'	TAT	GTCT	rgt	900
GAG'	TTG	CAT(CCA	AAA	AAA	AAA	AAA	AAA	AAA	A										931

FIG. 4A

•	•			4
1 MTDYRLQPTMNLWTTDDNASMMEAFMSSSDISTLWPPASTTTTATTETTPTAM 1 MTEYRSPPTMNLWT-DDNASVMEAFMSSSDFSSLWLPTPQSAASTTTPGADTARALPPPP 1MALSASPPA 1	56 EIPA OAGFNOETLOORLOALTEGTHEGWTYAIFWOPSYDFSG-ASVIGWGDGYYKGEEDK 60 PSOSOSLFNOETLOORLOTLIEGAEESWTYAIFWOSSYDYSSSTSLLGWGDGYYKGEEDK 12 EELLORPAEROLMRSOLAAAAR - SINWSYALFWSISDTO-P-GVITWTDGFYNG-EVK 10 EELLO-PAGRP-LRKOLAAAR - SINWSYALFWSISSTORP-RVITWTDGFYNG-EVK	115 ANPRRESS PFETPADQEYRKKVLREL-NSLISGGVARSD 120 GKGKAPKEMSSAEQDHRKKVLREL-NSLISGPFR-SA 66 TRKISNSVELTSDQLVMORSDQLRELYEALLSGEGDRRAAPARPAG 63 TRKISHSVELTADQLLMQRSEQLRELYEALRSGECDRRGARPVG	155 DAVDEEVTDTEWFFLVSMTQSFACGAGLAGKAFATGNAVWVSGSDQLSGSGCERAKQGGV 155 DDVDEEVSDTEWFFLVSMTQSFLSGSGLPGQAFLNSSPVWVAGADRLSDSTSBRARQGQV 112 SLSPBDLGDTEWYYVVSMTYAPRPGQGLPGRSFASDEHVMLCNAHLAGSKAFPRALLAKS 107 SLSPBDLGDTEWYYVICMTYARLPGQGLPGRSSASNEHVWLCNAHLAGSKDFPRALLAKS	215 FGMHTTACTPSANGVVEVGSTEPTROSSDLINKVRILFNFDGGDGDLSGLNWNLDEDQGE 215 FGVOTLVCTPSANGVVELASTEVIFONSDLMKKVRDLFNFNNFDD AGFWPLN - QGE 172 ASTOSTLCTPVMGGVLELGTTDTVPEAPDLVS RATAAFWEPQCP SSSPSGRA 167 ASTOTLVCTPLMGGVLELGTTDKVPEDPDLVS RATVAFWEPQCPTYSKEPSSNPS A 167 ASTOTLVCTPLMGGVLELGTTDKVPEDPDLVS RATVAFWEPQCPTYSKEPSSNPS A 167 ASTOTLVCTPLMGGVLELGTTDKVPEDPDLVS RATVAFWEPQCPTYSKEPSSNPS A
rd22BPI PG1 Lc B-Peru SGT10166	rd22BPI PG1 Lc B-Peru SGT10166	rd22BPI PG1 Lc B-Peru SGT10166	rd22BPI PG1 Lc B-Peru SGT10166	rd22BPI PG1 Lc B-Peru SGT10166

275 NDPS-MWINDPIGTPGSNEPGNGAPSSSQLFSKS-IQFENGSSSTITENDNLDPTPSPV 269 NDPSSLWLNPSSSIEIKDTSNAVALVSANASLSKT-MPFETPGSSTLTETBSAAA 224 NETGEAAADDGTFAFEELDHNNGMDDIEAMTAAGG-HGQEEELKLREAEALSDDASLE 223 YETGEAAYIVVLEDLDHN-AMDMETVTAAAGRHGTGQELGEVESPSNASLE 231 YETGEAAYIVVLEDLDHN-AMDMETVTAAAGRHGTGQELGEVESPSNSFER	333 HSQTQNPKENNTFSRELNFSDVKFYFSERRSGEILNFGDEGKRSSGNPDPSSYSGQTQFE 323 AAHVPNPKNQGFFPRELNFSNSLKPESGEILSFG-ESKKSSYNGSYFPGVAAEE 281 HTTKETEERY-SLCDEMDLQALPLPLEDGWTWDASNFEVPCSSPQEPPVDRATANV 273 HTTKGTDERY-SLCEEMDVQPLEDAWIMDGSNFEVPSSALPVD 6 25 QILSRTPTAQPSSPSSPPKSTNWSSABTFFPS	393 -NKRKRRSPANDLNEDKVLSF	426 VVVKEVA VE KR PKKRGRKPA NG REE PLNHVEAERORREKLNO 431 VVKEADSRVVEPEKRPRKRGRKPG NG REE PLNHVEAERORREKLNO 378 AIEEPOR - LLK - KVVAGGGAMES CGG ATGAAOEMSGTGTKNHVMSERKRREKLNE 346 VIBEPOK - LLK - KALAGGGAMANTNCGGGGTTVTAOEN GAKNHVMSERKRREKLNE 56 74 YAFEHKR SGAKQRNSLKR NID AQFHNLSEKKRRSKINE
rd22BPI	rd22BPI	rd22BPI	rd22BPI
PG1	PG1	PG1	PG1
Lc	Lc	Lc	Lc
B-Peru	B-Peru	B-Peru	B-Peru
SGT10166	SGT10166	SGT10166	SGT1016

-1G. 4B-2

```
SLISK
ARSSK
ALRKA
SLRKA
                                                   R R V V V V O O O O M
L L R
                \alpha
                                                  - DMSSSCSSIKPVGMEIEVKIIG-WDAMIII
SNKEAKETTSKLIDLELEVKIIG-WDAMII
DDVERPPVLTMDAGTSNVTVTVSDKDVLTI
GAKEHPWVLPMD-GTSNVTVTVSDTNVLLI
ETLEQDLNLETLIAAPHSLEPAK---TSK
                                                                                                SVVND LM - I QQATVKMGFRIYTQDQERA
VVVND LM - I QQATVNMGNRFYTQEQLRSI
A PDGFMGDKIRAQFAGSGAVVPWNTSEI
A PDGFMREKIGAQFAGSGAVVPGNISQ
               团
                S
          ı Q
                ø
  O EI CI
                        - 1
 VKTESEK
SELESEK
SELESSR
ELESRR
TLEAVMN
ASLLGDATAYINELKSKVVKI
ASLLGDATSYINELKSKLSE
ASTLAETIAYLKELQRRVQBI
ASTLAETIAYLKELQRRVQBI
ASMLDEATEYLKQLQLQVQTU
                                                                                                   RLMSALMDLELEVNHASMSV
RLMAALKELDLDVNHASVSV
RVFDATKSLHLDVLSVQASAI
RVFDATKSLHLDVLSVQASAI
                                                        - RKASPSGG--
- KSPSPPPGPP--
- KRKSPELGR-
SKRKSPEFAG--
  KMDKAS
KMDKAS
KRVINKAS
KKVDKAS
                                                          1 1 1 0
                                                      7
   REYALRAVVENVSK
REYALRAVVENVSK
MFLVLKSLEPSTHR
MFLVLKSLVESTHR
KMKALQKLIPNSNK
-><-
                                                                                                     A R
TTR
                                                                                                     SSKRNHPAA
CSKKNHPAA
CRWEELLMT
CRWEKLLMT
                                                                                                                                                   G - - -
G N A L
G K R -
G K R -
                                                                                                                                                    H H H
                                                                                                                                                    622
638
607
559
                                                                                                       563
579
547
499
203
                                                         512
522
491
443
155
     467
477
431
400
112
                                                                               B-Peru
SGT10166
                                   SGT10166
                                                                                                                                      SGT1016
                                                                                                                                                     rd22BPI
                                                         rd22BPI
PG1
                                                                                                        rd22BPI
                                                                                                                              B-Peru
     rd22BPI
                   Lc
B-Peru
                                                                                                               PG1
                                                                                                                      З
             PG1
                                                                        \Gamma_{\rm C}
```

PG1

8/8

(1) Wildtype ALC: GAAGAGGAGGA GCAAGATCAAC

(2) Ds tagged alc: GAAGAGGAGGA CCT AGAGGA GCAAGATCAAC

(3) Revertant: GAAGAGGAGGA CCT TAAGGA GCAAGATCAAC

(4) alc10 GAGGAGGAGGA CCT CTGAGGA GCAAGATCAAC

FIG. 5

anai Application No

PCT/SG 01/00017 A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/29 C12N15/82 C12N15/11 C07K14/415 A01H5/00 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED $\begin{tabular}{ll} Minimum documentation searched (classification system followed by classification symbols) \\ IPC 7 C12N C07K A01H \\ \end{tabular}$ Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EMBL, BIOSIS, EPO-Internal, WPI Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Category ° Relevant to claim No. DATABASE EMBL [Online] Х 1-9 ACCESSION NO: ABO20742, 13-17. 14 December 1998 (1998-12-14)
NAKAMURA, Y., ET AL.: "Arabidopsis 19,21, 24-28 thaliana genomic DNA, chromosome 5, TAC clone:K21H1. XP002149439 the whole document -& SATO, S., ET AL.: "Structural analysis of Arabidopsis thaliana chromosome 5. X. Sequence features of the regions of 3,076,755 bp covered by sixty P1 and TAC clones." DNA RESEARCH, vol. 7, 28 February 2000 (2000-02-28), pages 31-63, XP000946868 page 41 -/--Further documents are listed in the continuation of box C. X. Patent family members are listed in annex. Special categories of cited documents: T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled in the art. "P" document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 20.06.01 14 June 2001 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,

Fax: (+31-70) 340-3016

1

Maddox, A

International Application No PCT/SG 01/00017

		PCT/SG 0	1/0001/
C.(Continua	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		· · · · · · · · · · · · · · · · · · ·
Category °			Relevant to claim No.
A	SUNDARESAN VENKATESAN ET AL: "Patterns of gene action in plant development revealed by enhancer trap and gene trap transposable elements." GENES & DEVELOPMENT, vol. 9, no. 14, 1995, pages 1797-1810, XP000946848 ISSN: 0890-9369 the whole document	·	

International Application No
PCT/SG 01/00017

	PC1/3G 01/0001/
ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
EP 1 033 405 A (CERES INC) 6 September 2000 (2000-09-06) See SEQ ID NOS:29719-29722	1-3, 10-19, 21-28
DATABASE EMBL [Online] ACCESSION NO: B61971, 21 November 1997 (1997-11-21) ROUNSLEY , S.D., ET AL.: "T19M21TF TAMU Arabidopsis thaliana genomic clone T19M21, genomic survey sequence." XP002149440 the whole document	1-9
DATABASE EMBL [Online] ACCESSION NO:AI484932, 17 March 1999 (1999-03-17) ALCALA, J., ET AL.: "EST243195 tomato ovary, TAMU Lycopersicon esculentum cDNA clone cLED1H9,mRNA sequence" XP002149441 the whole document	1-9
WO 99 00502 A (UNIV CALIFORNIA) 7 January 1999 (1999-01-07) the whole document	1-28
KEMPIN ET AL: "The FRUITFULL MADS-box gene mediates cell differentiation during Arabidopsis fruit development" DEVELOPMENT, vol. 125, no. 8, 1 April 1998 (1998-04-01), pages 1509-1517, XP002082111 ISSN: 0006-4971 the whole document	1-28
PARINOV SERGUEI ET AL: "Analysis of flanking sequences from Dissociation insertion lines: A database for reverse genetics in Arabidopsis." PLANT CELL, vol. 11, no. 12, December 1999 (1999-12), pages 2263-2270, XP002149437 ISSN: 1040-4651 the whole document	
	EP 1 033 405 A (CERES INC) 6 September 2000 (2000-09-06) See SEQ ID NOS:29719-29722 DATABASE EMBL [Online] ACCESSION NO: B61971, 21 November 1997 (1997-11-21) ROUNSLEY , S.D., ET AL.: "T19M21TF TAMU Arabidopsis thaliana genomic clone T19M21, genomic survey sequence." XP002149440 the whole document DATABASE EMBL [Online] ACCESSION NO:AI484932, 17 March 1999 (1999-03-17) ALCALA, J., ET AL.: "EST243195 tomato ovary, TAMU Lycopersicon esculentum cDNA clone cLED1H9,mRNA sequence" XP002149441 the whole document WO 99 00502 A (UNIV CALIFORNIA) 7 January 1999 (1999-01-07) the whole document KEMPIN ET AL: "The FRUITFULL MADS-box gene mediates cell differentiation during Arabidopsis fruit development" DEVELOPMENT, vol. 125, no. 8, 1 April 1998 (1998-04-01), pages 1509-1517, XP002082111 ISSN: 0006-4971 the whole document PARINOV SERGUEI ET AL: "Analysis of flanking sequences from Dissociation insertion lines: A database for reverse genetics in Arabidopsis." PLANT CELL, vol. 11, no. 12, December 1999 (1999-12), pages 2263-2270, XP002149437 ISSN: 1040-4651 the whole document

information on patent family members

PCT/SG 01/00017

Patent document cited in search repor	ì	Publication date		atent family member(s)	Publication date
EP 1033405	Α	06-09-2000	NONE		
WO 9900502	A	07-01-1999	US AU CN CN EP EP WO US	6198024 B 8168698 A 8376098 A 1271388 T 1272885 T 1002087 A 0998566 A 9900503 A 6229068 B	06-03-2001 19-01-1999 19-01-1999 25-10-2000 08-11-2000 24-05-2000 10-05-2000 07-01-1999 08-05-2001

This Page is inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

X	BLACK BORDERS
Ä	IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
X	FADED TEXT OR DRAWING
\times	BLURED OR ILLEGIBLE TEXT OR DRAWING
×	SKEWED/SLANTED IMAGES
Ò	COLORED OR BLACK AND WHITE PHOTOGRAPHS
	GRAY SCALE DOCUMENTS
	LINES OR MARKS ON ORIGINAL DOCUMENT
	REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
	OTHER:

IMAGES ARE BEST AVAILABLE COPY.
As rescanning documents will not correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox